

UNITED STATES INTERNATIONAL TRADE COMMISSION

In the Matter of:) Investigation No.:
DIOCTYL TEREPHTHALATE (DOTP) FROM KOREA) 731-TA-1330 (PRELIMINARY)

REVISED AND CORRECTED

Pages: 1 - 115
Place: Washington, D.C.
Date: Thursday, July 21, 2016



Ace-Federal Reporters, Inc.

Stenotype Reporters

1625 I Street, NW

Suite 790

Washington, D.C. 20006

202-347-3700

Nationwide Coverage

www.acefederal.com

1 THE UNITED STATES
2 INTERNATIONAL TRADE COMMISSION
3 IN THE MATTER OF:) Investigation No.
4 DIOCTYL TEREPHTHALATE (DOTP)) 731-TA-1330
5 FROM KOREA) (PRELIMINARY)

6

7

8

9

10

11 Thursday, July 21, 2016
12 Hearing Room A
13 U.S. International Trade
14 Commission
15 500 E Street, SW
16 Washington, D.C.

17

18 The conference commenced pursuant to notice at 9:30
19 a.m., before the Investigative Staff of the United States
20 International Trade Commission, Elizabeth Haines,
21 Supervisory Investigator, presiding.

22

23

24

25

1 APPEARANCES:

2 On behalf of the International Trade Commission:

3 Staff:

4 Sharon Bellamy, Program Support Specialist

5 Sonia Parveen, Student Intern

6

7 Keysha Martinez, Investigator

8 Jeffrey Clark, International Economist

9 Charles Yost, Accountant/Auditor

10 Jane Dempsey, Attorney/Advisor

11 Elizabeth Haines, Supervisory Investigator (Presiding)

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 APPEARANCES:

2 Opening Remarks:

3 Petitioners (Christine M. Streatfeild, Baker &

4 McKenzie LLP)

5 Respondent (Mara M. Burr, Jochum Shore & Trossevin, PC)

6

7 In Support to the Imposition of Antidumping Duty Order:

8 Baker & McKenzie LLP

9 Washington, DC

10 on behalf of

11 Eastman Chemical Company

12 Cari Parker, Vice President, Chemical Intermediates and

13 Fibers Manufacturing, Eastman Chemical Company

14 Dr. Stephen R. Cullen, Business Unit Director, Oxo and

15 Plasticizers, Chemical Intermediates Business Organization,

16 Eastman Chemical Company

17 Brian A. Yobst, Strategic Procurement Manager, Eastman

18 Michael K. Carrier, Esq., Senior Counsel, Global Trade

19 and Compliance, Eastman Chemical Company

20 Thomas Rogers, Economist, Capital Trade, Inc.

21 Kevin M. O'Brien and Christine M. Streatfeild - Of

22 Counsel.

23

24

25

1 In Opposition to the Imposition of Antidumping Duty Order:

2 Jochum Shore & Trossevin, PC

3 Washington, DC

4 on behalf of

5 ALAC International Inc.

6 Ted Fisher, Director of Sales and Marketing, ALAC

7 International Inc.

8 Mara M. Burr - Of Counsel

9

10 Rebuttal/Closing Remarks:

11 Petitioners (Kevin M. O'Brien, Baker & McKenzie LLP)

12 Respondent (Mara M. Burr, Jochum Shore & Trossevin, PC)

13

14

15

16

17

18

19

20

21

22

23

24

25

1 I N D E X

2		Page
3	Opening Remarks:	
4	Petitioners (Kevin M. O'Brien, Baker & McKenzie LLP)	7
5		
6	Respondent (Mara M. Burr, Jochum Shore & Trossevin, PC)	10
7		
8	Cari Parker, Vice President, Chemical Intermediates	14
9	and Fibers Manufacturing, Eastman Chemical Company	
10		
11	Dr. Stephen R. Cullen, Business Unit Director, Oxo and	21
12	Plasticizers, Chemical Intermediates Business	
13	Organization, Eastman Chemical Company	
14		
15	Brian A. Yobst, Strategic Procurement Manager, Eastman	31
16		
17	Thomas Rogers, Economist, Capital Trade, Inc.	37
18		
19	Ted Fisher, Director of Sales and Marketing, ALAC	84
20	International Inc.	
21		
22	Rebuttal/Closing Remarks:	107
23	Petitioners (Kevin M. O'Brien, Baker & McKenzie LLP)	
24		
25	Respondent (Mara M. Burr, Jochum Shore & Trossevin, PC)	112

1 P R O C E E D I N G S

2 MS. HAINES: Good morning, and welcome to the
3 U.S. International Trade Commission conference in
4 connection with the preliminary phase of the antidumping
5 duty Investigation 731-TA-1330, concerning dioctyl
6 terephthalate, DOTP, from Korea.

7 My name is Elizabeth Haines, I'm the supervisory
8 investigator in the Office of Investigations, and I will
9 preside at this conference.

10 Among those present from the Commission
11 Investigative Staff are, to my far right, Charles Yost,
12 accountant/auditor, Keysha Martinez, investigator, Jane
13 Dempsey, attorney/advisor, and Jeffrey Clark, economist.

14 I would like to remind speakers not to refer in
15 your remarks to business proprietary information and to
16 speak directly into the microphones. We also ask that you
17 state your name and affiliation for the record before
18 beginning your presentation or answering questions for the
19 benefit of the court reporter.

20 All witnesses must be sworn in before presenting
21 testimony.

22 I understand parties are aware of the time
23 allocations. Any questions regarding time allocations
24 should be addressed with the Secretary.

25 Are there any questions?

1 Madam Secretary -- are there any preliminary
2 matters?

3 MS. BELL: No, Madam Chairman.

4 MS. HAINES: Very well. Let us proceed with the
5 opening remarks.

6 MS. BELL: I'll announce her to come up.

7 MR. O'BRIEN: Ms. Haines, would you mind if I
8 close the door?

9 MS. HAINES: Sure.

10 MS. BELL: Opening remarks on behalf of
11 Petitioner, Christine M. Streatfeild, Baker McKenzie LLP.

12 OPENING REMARKS OF CHRISTINE M. STREATFEILD

13 MS. STREATFEILD: Good morning, Madam Director
14 and Commission Investigative Staff. I am Christine
15 Streatfeild of Baker & McKenzie and I represent the
16 Petitioner, Eastman Chemical Company.

17 We're here today to ask for relief from unfairly
18 traded imports of dioctyl terephthalate from Korea. The
19 record of this investigation makes clear that Korean import
20 volumes are growing exponentially and that U.S. prices have
21 been in a free-fall across the entire market.

22 Eastman is the only U.S. producer of the
23 domestic like product, which is DOTP coextensive with the
24 proposed scope of this investigation.

25 DOTP is a commodity product that is produced to

1 industry specifications and is highly interchangeable,
2 regardless of source or the method of manufacture.

3 Price is the primary factor for purchasing
4 decisions. Eastman produces DOTP at its two facilities in
5 Kingsport, Tennessee, and Texas City, Texas. There is no
6 question that Eastman's DOTP operations have been
7 materially injured. And there's also no question on this
8 record that it presents a reasonable indication that that
9 injury is by reason of subject imports.

10 The data, for example, show a drop in Eastman's
11 pricing, which tracks the declining Korean pricing. The
12 data shows costs declining and price decreases overwhelming
13 those declines.

14 Simply put, the data show that there's a
15 reasonable indication that the subject imports are more
16 than a minimal or tangential cause of injury.

17 When the Commission applies the statutory
18 factors, it's evident that subject imports are the cause of
19 the injuries suffered by Eastman. Subject imports are
20 undoubtedly significant. They have increased, and that
21 increase is significant.

22 Imports from Korea represented about 40 percent
23 of imports in 2013 and 72 percent of all imports in the 12
24 months prior to April 2016. Korea is the leading foreign
25 producer of DOTP, supplier of DOTP, during the entire

1 period of investigation.

2 Korean imports held a considerable share of U.S.
3 consumption since 2013, and these imports have also
4 increased relative to all U.S. imports.

5 As you will hear from our witnesses today,
6 Korean product was virtually nonexistent in the U.S. market
7 prior to 2010. The increase in Korean imports and the
8 gains in market share would have been greater had Eastman
9 not reduced its prices substantially to avoid even more
10 lost sales.

11 Now, our witnesses today will explain that
12 Eastman has lost substantial sales to lower-priced imports
13 and has been forced to lower its prices to avoid further
14 slippage. Our witnesses will also explain the financial
15 impact that Korean imports have had on the business unit.

16 The result is millions of dollars in lost
17 revenue, a planned expansion that's had to be shelved and
18 declining costs that are swallowed up by more severely
19 dropping prices.

20 We also believe that the data will show Korean
21 imports underselling Eastman. The result is that the
22 Korean product has driven down the price of DOTP in the
23 U.S. market.

24 The Commission doesn't need to addresses threat
25 of injury here, given the strong indication of present

1 material injury, but threat is even more stark.

2 The Korean producers have staggering
3 overcapacity and have demonstrated a U.S. export focus. The
4 upward trend of imports continues through April 2016,
5 where, when import data is compared to the previous year to
6 date data, Korean import volumes are up almost 16 percent,
7 while average unit values have dropped 30 percent. This
8 data is plain enough.

9 The domestic industry requests only a level
10 playing field on which to fairly compete. We sincerely
11 appreciate the Commission's time and attention to this
12 investigation. Thank you very much.

13 MS. BELL: Opening remarks on behalf of
14 Respondent, Mara M. Burr, Jochum, Shore and Trossevin, PC.

15 OPENING REMARKS OF MARA M. BURR

16 MS. BURR: Good morning. It's very nice to be
17 here.

18 Madam Chair, members of the International Trade
19 Commission, I am here on behalf of ALAC, an importer of the
20 subject product DOTP. And we are here to refute in some
21 respects the claims of the petitioner about injury in the
22 market. Our witness will talk a little bit about the
23 complexities of this market, the complexities of the market
24 in the United States, and the complexities of the market
25 globally.

1 We do find it interesting that the Petitioner
2 does not address a few issues that are very important.
3 First of all, the entry into force of the U.S.-Korea free
4 trade agreement. As the International Trade Commission
5 does the economic analysis of trade agreements, it is quite
6 clear that for products that go to zero on entry into
7 force, there is usually a substantial increase in imports
8 if the producers are competitive in the market, which the
9 Korean producers are.

10 So the period that we're talking about, 2013 to
11 2016, coincides with the entry into force of KorUS, as it's
12 called, or U.S.-Korea free trade agreement, and that, in my
13 experience, is how free trade agreements are supposed to
14 work. You lower the duties, and imports increase for both
15 sides. That's why the United States negotiates free trade
16 agreements.

17 The result of KorUS was to remove a 6.5 percent
18 tariff from the subject product, DOTP. This made Korea
19 very competitive in the market because it went to a zero
20 duty rate, where other countries continued to pay the 6.5
21 percent rate.

22 I think it's very important to also note that
23 this is a product, an oil-based product, that is subject to
24 fluctuations based on oil prices. And the inputs for DOTP
25 are dependent on oil-, petroleum-based derivatives.

1 So of course, in the last few years, we've seen
2 unprecedented drops in the price of oil. And I think that
3 must be taken into account by the International Trade
4 Commission as you look at the factors that both cause an
5 increase in imports and pricing issues.

6 On the pricing issues as well, I think there is
7 more complexity here than meets the eye. With respect to
8 the amount of Korean imports coming into the United States
9 and the capacity of the Petitioner, I think it's quite
10 clear that the imports, although somewhat significant, are
11 not significant in the market compared to the production
12 capacity of the Petitioner. And that must be taken into
13 account by the International Trade Commission.

14 For these reasons, we do not believe that the
15 domestic industry has been materially injured, and we
16 believe there are much more -- many more issues that need
17 to be taken into account going forward, to get a basic
18 understanding of how this market works, how this product is
19 sold and why it is that Korean imports have increased.

20 It's also very important to note, as our witness
21 will go over, that for the type of industry we're talking
22 about, you need to have multiple suppliers, and multiple
23 suppliers are very important. And, in fact, in Eastman's
24 petition and in its annual report, it talks about time to
25 time that there are shortages and where demand exceeds

1 production.

2 So for these reasons, we think it's very
3 important that when looking at the entire market and
4 looking at all of the factors, the International Trade
5 Commission will come to the conclusion that the petitioner
6 is not being materially injured by imports from Korea.
7 Thank you.

8 MS. BELL: Petitioners can come forward.

9 MR. O'BRIEN: Good morning, Ms. Haines and
10 Commission Investigative Staff. I am Kevin O'Brien from
11 Baker & McKenzie, and we have several witnesses that would
12 like to offer testimony this morning, and we welcome the
13 Commission's attention to this important case.

14 I'd like to introduce the witnesses right now,
15 if I can. To my immediate left is Ms. Cari Parker, vice
16 president, chemical intermediates and fibers manufacturing,
17 Eastman Chemical Company.

18 Following Ms. Parker's statement will be a
19 statement by Dr. Stephen Cullen, business unit director,
20 oxo and plasticizers, chemical intermediates business
21 organization, Eastman Chemical.

22 And after Dr. Cullen, Brian Yobst will speak,
23 the strategic procurement manager for Eastman.

24 We also have at the far end Michael Carrier,
25 senior counsel, global trade and compliance, Eastman

1 Chemical. And following Mr. Yobst, Thomas Rogers will
2 speak. He is our economist on behalf of capital trade.

3 With that, I will turn to Ms. Parker for our
4 first witness statement.

5 MS. PARKER: Good morning, Ms. Haines and the
6 rest of the Commissioners. I am Cari Parker, vice
7 president of chemical intermediates and fibers
8 manufacturing for Eastman. I am a chemical engineer by
9 training, and I began working for Eastman in 1987.

10 I've held positions of increasing responsibility
11 in several areas, including technology, human resources and
12 manufacturing operations in Tennessee and Texas.

13 I've been associated with the plasticizer
14 business since 2005, when I became a leader of plasticizer
15 manufacturing in Kingsport. I subsequently held leadership
16 positions in our technology organization, with
17 responsibility for plasticizer process improvement and
18 development.

19 I am currently responsible for global
20 manufacturing operations for our chemical intermediates and
21 fibers segments. More specifically, I'm responsible for
22 Eastman's plasticizer manufacturing, including DOTP
23 production units in Kingsport, Tennessee, and Texas City,
24 Texas.

25 This case is of critical importance to our

1 company and to our DOTP operations in both Tennessee and
2 Texas, and I very much appreciate the opportunity to be
3 here to address the Commission this morning.

4 To provide some company background, Eastman is a
5 global specialty chemical producer, headquartered in
6 Kingsport, Tennessee. We've been producing in the United
7 States since 1920. Eastman's founder, George Eastman,
8 established our facility in Kingsport following the
9 outbreak of World War I, which caused a scarcity of raw
10 materials, including many chemicals, that were needed to
11 make photographic paper. Photographic processes were of
12 course a cornerstone business for our company at that time,
13 as we were part of Eastman Kodak.

14 George Eastman was determined to provide an
15 independent supply of chemicals and it's from his
16 determination that many of Eastman's basic building blocks
17 were developed, manufactured and perfected.

18 In 1994, Eastman Chemical Company split off from
19 Eastman Kodak and became an independent corporation.
20 Eastman's innovative products have made us a leader in the
21 global chemical industry for more than 90 years. We have
22 now roughly 15,000 employees, with about 6500 in Tennessee
23 and another roughly 1000 in Texas at our Longview and Texas
24 City sites.

25 We've received numerous corporate citizen

1 awards, including the Glassdoor Employee's Choice Award
2 recognizing the best places to work for 2014, '15 and '16.

3 We received the CR Magazine Top 100 Best
4 Corporate Citizens Award in 2015 and the Energy Star Award
5 for five consecutive years from 2012 through 2016.

6 These awards show our commitment to the
7 community and to those we employ in those communities.
8 Eastman is the only U.S. manufacturer of DOTP and was the
9 first-ever producer beginning in 1974.

10 We were manufacturing in Kingsport, Tennessee,
11 then and today, after more than 40 years, we are still
12 manufacturing at that site.

13 In 2011, we expanded our operations through the
14 acquisition of a site in Texas City. Because of increased
15 worldwide demand for DOTP, we wanted to expand our
16 capacity, and as we evaluated options for that expansion,
17 we learned that Sterling Chemicals, Incorporated had closed
18 its Texas City plasticizer unit, laying off all of the
19 workers and idling assets due to the reduction in demand
20 for phthalate plasticizers.

21 Eastman acquired Sterling in 2011 for \$100
22 million. A press release announcing this acquisition
23 noted, this acquisition includes Sterling's plasticizer
24 manufacturing assets in Texas City, Texas. Eastman plans
25 to modify and restart the currently idled plasticizer

1 manufacturing facility to produce nonphthalate
2 plasticizers, including Eastman 168 nonphthalate
3 plasticizer. This additional capacity will enable the
4 company's performance chemicals and intermediate segment to
5 serve the growing demand for nonphthalate alternatives.

6 I was the first site leader after our
7 acquisition of the Texas City site. I oversaw the retrofit
8 of the plasticizer unit and the start-up in 2012. As part
9 of this process, we hired previously laid off employees and
10 transformed the site into a more productive asset.

11 The Texas City site included multiple
12 manufacturing units over its many decades of history. Over
13 a number of years, unit after unit was shut down. By the
14 time Sterling closed the plasticizer unit at the end of
15 2010, only one other unit was operating. Eastman's
16 acquisition revitalized the location and represented a new
17 start. In fact, one of the first things we were able to do
18 was rehire workers who had been made redundant when the
19 plasticizer unit was closed.

20 We expanded our DOTP production in response to
21 increased global demand. We were correct in our assessment
22 that global DOTP would grow strongly, which was the reason
23 behind the acquisition in Texas City and expansion in
24 Kingsport. But we didn't anticipate the price effects
25 caused by the Korean imports entering the U.S. at

1 increasing volumes and continually lower prices.

2 Our sales volume has grown significantly, but we
3 had progressively lost market share over several years.
4 Profitability has continued to deteriorate to the point
5 that we can no longer justify additional capacity
6 expansions in response to market need.

7 The product subject to this investigation, DOTP,
8 is a nonphthalate plasticizer that is used primarily in the
9 manufacture of plastics, and most importantly, flexible PVC
10 consumer products. DOTP is a substance that is added to
11 plastics to impart softness, making them easier to handle.
12 It is used in PVC articles such as flexible flooring, vinyl
13 wall coverings, mats and toys.

14 DOTP is what we would call a general purpose or
15 primary plasticizer. That means it can be used for most
16 flexible PVC applications as the main plasticizing
17 component. And because of that, DOTP is used in commerce
18 in large quantities.

19 Eastman recognized the emerging market need for
20 an alternative to phthalate plasticizers for use in
21 everyday consumer products. Furthermore, Eastman invested
22 in capacity in advance of this emerging need so that
23 material was available for those who needed to or chose to
24 switch.

25 Eastman has also invested significantly in

1 developing the technical know-how to help our customers
2 make the conversion from using a phthalate plasticizer to a
3 nonphthalate plasticizer.

4 We are here today to ask the Commission for
5 relief regarding the unfairly traded imports that are
6 destroying our DOTP business. We have lost tens of
7 millions of dollars in sales revenue due to the dumped
8 imports. These considerable price and volume effects have
9 devastated our bottom line, as you have seen in the
10 confidential data contained in our questionnaire response.

11 We have suffered substantial declines in
12 profitability from 2013 through today. This decline has
13 directly affected our plans to grow the DOTP business.
14 We've been forced to abandon expansion plans, which has an
15 impact not only on our business segment but on the
16 communities in which we are a significant employer.

17 The dumping of Korean product that has occurred
18 has dramatically lowered the commercial price of Eastman's
19 U.S.-produced DOTP due to the underselling by the Korean
20 suppliers.

21 Our profitability in the market has been
22 substantially reduced. These trends are not sustainable.

23 Eastman is known for high quality chemical
24 products, including DOTP. We are a world-class company
25 that routinely and successfully competes with the largest,

1 most sophisticated chemical producers in the world.

2 We seek only a level playing field. We've been
3 producing this product in the U.S. for more than 40 years.
4 Until 2010, we had a relatively modest volume of domestic
5 sales of DOTP on which we realized an acceptable profit.

6 Coincidentally, there was basically no Korean
7 DOTP in the U.S. market at that time.

8 During 2011 and forward, market conditions
9 changed rapidly and precipitously. The Korean producers,
10 LG Chem, Aekyung and Hanwha, entered the U.S. market in
11 force and have undercut the U.S. price time and again.

12 We believe this is as a result of Korea having
13 several times more capacity for DOTP production than is
14 needed for its domestic consumption. Korean producers have
15 rapidly sought western outlets for their excess capacity
16 using price as a basis of competition.

17 By 2013, Korean imports were significant and on
18 a staggering growth trajectory. Because DOTP is a
19 commodity, those lower-priced Korean imports steadily
20 increased market share. While demand has increased, for
21 reasons we will further address, unrelenting price
22 reductions have cut Eastman's price in half since 2013,
23 well beyond any changes in raw material costs.

24 Eastman has attempted to differentiate itself
25 from these Korean imports as a high quality, reliable

1 domestic supplier. However, significant import quantities
2 have come into the U.S. market with only price as a basis
3 of competition and supply is now wholly commoditized. This
4 product is now generically referred to as DOTP.

5 We have made repeated price reductions in direct
6 response to Korean competitive pricing, as we discussed in
7 detail in our petition. We have done this to avoid further
8 volume losses with our customers and to keep our lines
9 running on a 24-hour, 7-day-per-week schedule, which is
10 essentially to efficiently produce DOTP.

11 Confidential financial data contained in our
12 petition tells the story, including millions of dollars
13 lost as we face downward pricing pressure from our
14 customers here. And we've been unable to justify further
15 development and expansion of our DOTP lines. This means
16 jobs have not been created and capital expenditures could
17 not be justified.

18 Eastman can and does successfully compete in the
19 U.S. market. All we ask for is a level playing field. For
20 these reasons, we ask the Commission, on behalf of our
21 management team and our employees, to make an affirmative
22 determination here. Thank you.

23 MR. O'BRIEN: We will now hear from Dr. Stephen
24 Cullen.

25 DR. CULLEN: Good morning. My name is Steve

1 Cullen, and I'm the business unit director for Eastman's
2 oxo and plasticizer businesses. I have global profit and
3 loss responsibility for the upstream oxo business, and
4 that's the main raw materials that are used to make
5 plasticizers, amongst other derivatives, as long as the
6 downstream plasticizer businesses.

7 I have an honors degree in PhD and chemistry
8 from the University of York in the U.K. and have been in
9 commercial roles in the chemical industry for the whole of
10 my career, which so far spans 22 years.

11 I've been with Eastman for 14 years and directly
12 involved in the plasticizer business for the last 8-1/2
13 years.

14 I relocated to the U.S. in 2008 to take up the
15 position of business manager for the plasticizer business,
16 during one of the greatest periods of change in the
17 industry.

18 In 2011 and 2012, I held a role focused on
19 developing the long-term plasticizer business strategy,
20 before resuming profit and loss responsibility as the
21 business director for the plasticizer businesses in 2012.

22 I will testify today about the manufacturing
23 process for DOTP and on other aspects of this product.

24 Eastman produces DOTP at its Kingsport,
25 Tennessee, and Texas City, Texas, facilities. Eastman is

1 also integrated into the manufacture of the key raw
2 materials used in the production of DOTP.

3 These are terephthalic acid, also known by the
4 acronym PTA, and dimethyl terephthalate, known by the
5 acronym DMT. Both of these are made at our Kingsport,
6 Tennessee, location. The other key raw material is
7 2-ethylhexanol, also known by the acronym 2 EH, and that is
8 made at our Longview, Texas, and also Singapore facilities.

9 Our DOTP manufacturing units are dedicated to
10 the production of DOTP, both in Texas and in Tennessee. By
11 this we mean that no other products are made on those
12 lines.

13 Major global producers of DOTP use one of two
14 methods, either transesterification or direct
15 esterification.

16 Regardless of the production process that is
17 used, the end molecule is DOTP, which is a distinct
18 chemical entity.

19 Eastman chooses to use the first process that I
20 mentioned, the transesterification process, and we do this
21 for historical and operational convenience reasons.
22 Eastman is one of the few remaining producers worldwide of
23 DMT, so we have the option to use that available to us.

24 We could elect to use the PTA direct
25 esterification process instead, as the two processes and

1 the products coming from them are fully interchangeable,
2 and Eastman also manufactures PTA.

3 From a customer or end application perspective,
4 the final product is DOTP, regardless of the method of
5 manufacture.

6 Eastman's DOTP production generates methanol as
7 opposed to water as a by-product with using the
8 transesterification process. The methanol generated in our
9 production process is recycled back into our DMT
10 production, as opposed to the water which would be
11 generated from the direct esterification process, which
12 would have to be discarded.

13 We believe our highly integrated processes and
14 methanol recycle makes Eastman amongst the most efficient
15 producers of DOTP in the world.

16 As I mentioned, our DOTP is highly
17 interchangeable with DOTP from Korea. The products have
18 comparable specifications, comparable characteristics and
19 comparable properties.

20 They have the same customers and the same end
21 uses. This interchangeability means that producers are
22 able to switch back and forth between sources of DOTP based
23 on price. As a result, we have repeatedly been presented
24 with lower competitive bids for Korean product as a direct
25 substitute for our product.

1 Many of our customers have purchased Korean
2 product in place of ours during the past three years. We
3 describe in detail in our petition specific instances of
4 lost sales and lost revenue to the low price Korean
5 producers due to the highly interchangeable nature of U.S.
6 and Korean DOTP and use in the same final applications.

7 My colleague, Brian Yobst, will discuss the
8 regulatory framework governing plasticizers in the United
9 States and how that has had an impact on the U.S. demand
10 for DOTP in recent years.

11 However, it's worthwhile to take a moment to
12 describe why DOTP is unique and not interchangeable with
13 other plasticizer products and why its demand has grown so
14 quickly in the U.S. over the last six-plus years.

15 DOTP has a specific chemical structure that
16 imparts particular and increasingly desirable
17 characteristics. It is a nonphthalate, as opposed to an
18 ortho-phthalate, plasticizer or more commonly known as
19 phthalate plasticizers.

20 Phthalates are a class of compounds that have
21 been the industry standard plasticizers since at least the
22 1950s. Phthalate plasticizers have been increasingly
23 subject to controversy over carcinogenic and reproductivity
24 toxicity concerns seen in animal testing and, as a result,
25 increasing regulatory scrutiny.

1 For example, by the EPA and its chemical action
2 plan for phthalates, under the Consumer Product Safety
3 Improvement Act of 2009 that introduced regulation
4 prohibiting the sales of toys and mouthable children's
5 products using the most common phthalate plasticizers.

6 And also in the findings of the subsequent
7 Consumer Product Safety Commission chronic hazard advisory
8 panel, findings and recommendations.

9 In addition, the two most commonly used general
10 purpose phthalate plasticizers are listed under
11 California's Proposition 65 as materials which are known to
12 the state of California to cause adverse health effects.

13 We are not here to debate the highly complex
14 science of those arguments, but rather to state the facts
15 that regulation, consumer preference, and increasingly, the
16 choice of brand owners, has driven a technology shift away
17 from the use of traditional phthalate plasticizers and
18 leading to a significant growth in the demand of
19 nonphthalate plasticizers and, in particular, DOTP in
20 flexible PVC products in the U.S.

21 Simply put, DOTP is perceived quite differently
22 in the market to traditional phthalates by customers,
23 regulators and the public.

24 I'd also like to take a moment to briefly
25 explain the relevance of DOTP blends in this case. Cari

1 Parker has explained that DOTP is a general purpose, or
2 primary, plasticizer and that some applications also
3 utilize specialty or niche plasticizers in combination with
4 the primary plasticizer.

5 This is generally done to modify the end product
6 processing, rather than to change the properties of the
7 final PVC article. Eastman does sell blends in the United
8 States in small quantities for niche applications,
9 representing a de minimis portion of our DOTP sales.

10 Our primary market for blends is in Europe for
11 quite specific applications.

12 We do not believe that blends are being imported
13 into the United States from Korea. We have not seen any.
14 We included blends in this investigation to avoid the
15 potential for foreign producers to bypass an antidumping
16 order by first blending DOTP and then importing.

17 Again, we do not know of such imports at this
18 point. We also do not know of any purchasers who import
19 DOTP from Korea and then blend it in the United States
20 prior to sale. So we do not believe the blends are a
21 factor in the Commission's preliminary decision.

22 The Commission's questionnaire requested
23 information about another chemical that Eastman produces,
24 DBT, or which is otherwise known as dibutyl terephthalate.

25 DBT and DOTP are different chemicals. They have

1 different physical characteristics. A partial list of the
2 foundational distinctions between these two chemicals
3 includes that DOTP is a primary plasticizer, while DBT is a
4 secondary or niche plasticizer. DOTP is a liquid at room
5 temperature, while DBT is a solid.

6 DOTP -- DOTP and DBT are used differently and
7 stored differently. DBT is rarely used outside of blends,
8 whereas only a negligible volume of DOTP goes into blends.

9 DBT is a specialty plasticizer that is generally
10 used in combination with much greater quantities of another
11 general purpose plasticizer, unlike DOTP, which in itself
12 is a general purpose plasticizer.

13 Finally, DBT is sold through different channels
14 of distribution. Eastman did not sell DBT in the U.S. to
15 distributors over the past three years, while we have
16 routinely sold DOTP to distributors.

17 As a final point, DBT pricing is generally
18 higher than DOTP, and DBT pricing does not fluctuate in the
19 same way that DOTP does.

20 DOTP pricing fluctuates mainly on supply-demand
21 drivers, including the presence of competitive prices for
22 Korean product and based on raw material import costs.

23 DBT pricing does not fluctuate like this.

24 I've previously noted the increase in U.S.
25 demand for DOTP and would like to also point out that

1 Eastman has sufficient capacity to address these increases
2 in demand in the U.S. market. Eastman's existing capacity
3 could supply more than the current U.S. domestic
4 consumption of DOTP.

5 At no point over the past three years have we
6 been unable to supply customers with requested volumes of
7 DOTP in the U.S. through demand exceeding our capacity. We
8 have also described how we have invested in additional
9 capacity in advance of market growth.

10 We announced in 2014 that we had completed an
11 expansion at our Texas City facility and that we intended
12 to further expand our DOTP capacity at a later date.
13 However, as Cari Parker noted, despite significant volume
14 growth, the impact of Korean imports has caused the
15 profitability of this business to deteriorate to the point
16 that we cannot justify further investment in expansion of
17 our DOTP lines as we expected in 2014.

18 With respect to our costs, and particularly raw
19 material costs, we explained in our petition how Eastman's
20 cost of goods produced declined in recent periods. General
21 purpose plasticizers are petrochemical products, and so
22 under normal market conditions, selling prices would
23 fluctuate on the basis of raw material inputs.

24 We would expect, then, that prices would have
25 fallen based on the declining oil price in 2015, for

1 example. However, the declining DOTP pricing over the same
2 period has far surpassed the raw material cost declines.
3 So our revenue has declined over the same period that we
4 saw increased imports, and these imports were at lower and
5 lower prices.

6 Moreover, when oil prices increased again
7 earlier this year, pricing of DOTP did not move up in kind.
8 In fact, Eastman announced a price increase for DOTP to be
9 effective April 1 of this year.

10 In the end, the situation after this
11 announcement was that our overall average pricing was
12 lower. This is an example of how Korean import material is
13 so ubiquitous in the U.S. market that we have no pricing
14 power in our home market.

15 We provided the specific cost numbers in our
16 petition and the financial information makes the same
17 point.

18 Finally, competition with Korean imports occurs
19 both through the distributors or broker channel and on a
20 producer to user direct basis.

21 In the producer to user direct channel, Eastman
22 competes for orders with product that is usually packed in
23 20-metric-ton flexitainers, which is a bag contained inside
24 a normal 20-foot shipping container, or in proper chemical
25 isotainers, which are imported directly to the end user.

1 In the distributor/broker channel, Eastman
2 mainly competes for orders directly at end customers with
3 Korean DOTP that has been shipped to the U.S. in bulk sea
4 shipments, stored in a local shore tank and which is then
5 delivered to end users in tanker truck lots. Irrespective
6 of the method by which Korean DOTP arrives at the customer,
7 we have been required to set our pricing at or close to the
8 Korean competitive pricing in order to maintain volumes
9 even with our longtime customers.

10 Basically, regardless of how DOTP enters the
11 U.S., Eastman is competing with Korean DOTP for orders from
12 end users, 20 metric tons at a time.

13 Because the main basis for competition centers
14 on price, the effect of these increasing volumes of Korean
15 imports has been to drive down market prices.

16 In summary, low-priced imports from Korea have
17 seriously damaged our DOTP business and the trends indicate
18 that increasing import volumes of unfairly priced product
19 will continue. So we ask on behalf of our company and its
20 many stakeholders for an affirmative determination. Thank
21 you.

22 MR. O'BRIEN: We will now hear from Mr. Brian
23 Yobst.

24 MR. YOBST: Good morning. My name is Brian
25 Yobst. I am currently a strategic procurement manager at

1 Eastman, where I have responsibilities for procurement of
2 raw materials supporting Eastman's adhesives business. I
3 have been in the chemical industry for more than 20 years
4 and with Eastman for 15 years. I was a manufacturing
5 supervisor, a global pricing manager and was the business
6 unit manager of the general purpose plasticizer business
7 unit until moving to procurement in May of this year.

8 In my business unit manager role, I oversaw the
9 business that includes DOTP and was in charge of profit and
10 loss management, oversight of significant customer
11 negotiations and execution of our business strategy for
12 DOTP.

13 I would like to start with an overview of the
14 conditions of competition for DOTP in the U.S. market.
15 DOTP is a commodity product that is highly price-sensitive.
16 Demand for DOTP in the United States has increased over the
17 past three years, while prices have plummeted.

18 The reason for the increase in demand are the
19 ongoing technology shift toward nonphthalate plasticizers,
20 as you have heard. There are federal and state regulations
21 that ban or restrict the use of certain phthalate
22 plasticizers in specific end uses, or require labeling of
23 articles containing certain phthalate plasticizers.

24 As a result, DOTP has emerged as the leading
25 phthalate alternative for the manufacture of consumer

1 goods.

2 For example, our petition includes a description
3 of California's Proposition 65, which is intended to alert
4 California citizens to the presence of chemicals that may
5 cause cancer, birth defects or reproductive harm.

6 The California Prop 65 list includes several
7 phthalates, but does not include DOTP.

8 The trend that has emerged is that DOTP has
9 replaced phthalates in various applications, such as
10 textile printing, flooring and of course children's toys.

11 For Eastman, in the U.S., the largest end use
12 for DOTP is flexible flooring products. As we have seen an
13 increasing trend that major brand owners are restricting
14 use of phthalates in the manufacture of their products,
15 we've also seen major retailers, like Home Depot, Lowe's,
16 Menard's and Lumber Liquidators, make public statements
17 indicating they would phase out vinyl flooring products
18 containing phthalates.

19 In 2015, Home Depot instructed a half dozen
20 suppliers to phase out their use of phthalates in vinyl
21 flooring sold in its stores by 2016. Brand owner choices
22 such as these have been the main driver for the dramatic
23 increase of U.S. consumption of DOTP over the past six-plus
24 years.

25 In addition, DOTP not only has a comprehensive

1 and clean toxicological profile, such that it does not
2 appear on any restricted lists, but in fact it has received
3 positive risk assessments from several competent bodies,
4 including EPA and governmental agencies around the world.
5 In terms of other plasticizers, they are plainly not
6 substitutes for DOTP in this regulatory environment.

7 DOTP is sold in the United States to
8 distributors and end users. End users of DOTP produce
9 vinyl flooring for the retailers such as those I've just
10 described. In Eastman's experience, the majority of our
11 product is sold to end users, with a much smaller portion
12 sold to distributors. We do see seasonal sales trends with
13 stronger sales typically in March through October. This
14 aligns with the building and construction cycles and could
15 be influenced by the demands in the flooring market.

16 At Eastman, we stand behind our reputation for
17 quality and service, and we work tirelessly to maintain our
18 customer relations.

19 As a result, we have made long-standing
20 customers for DOTP. Over the past several years, Eastman
21 has experienced increased price pressure with specific
22 references to competitive Korean pricing. We were forced
23 to take Korean prices into account in key contract
24 negotiations. In an attempt to not lose further share, we
25 have had to make substantial price concessions. Even then

1 we have lost sales if we did not match the Korean offer.
2 We have had sales and contracts lost in the face of this
3 competition. We experience the impact of the Korean DOTP
4 every day with price pressure and volume impacts across our
5 customer base.

6 We provide specific instances of lost sales,
7 lost volume, lost revenue in our petition, but we ask the
8 Commission to consider that the pricing in the entire DOTP
9 market has dropped over this period.

10 The effect of these low prices is magnified when
11 the Commission views them in conjunction with the volume
12 surge. We have seen a dramatic increase in imports from
13 Korea. Such imports virtually did not exist prior to 2009.
14 Import statistics show remarkable increases. Imports
15 increasing nearly 500 percent between 2013 and 2015.

16 The percentage is significant enough, but the
17 volumes are also huge. These numbers show that the Korean
18 imports have captured an increasing portion of the U.S.
19 market, both in absolute terms and relative to other
20 countries.

21 Other countries' market share have dropped off
22 compared to the Korean's. That means that during a period
23 of considerable increases of demand in the United States,
24 imports for the rest of the world have lost share to the
25 Koreans.

1 Korean's customs authority reports export data,
2 and data going back to 2005 makes the very same point.
3 Export statistics show that the Koreans sent no product to
4 the United States until 2008, and even in 2008, the volumes
5 were minuscule.

6 But exports began growing exponentially year on
7 year after 2008, from about 1000 metric tons in 2010 to
8 more than 25,000 metric tons in 2015. From either the U.S.
9 import or the Korean export frame of reference, these
10 growth trends are unmistakable.

11 I would also like to take a moment to discuss
12 the future. As the import trends make clear, the U.S. has
13 become a critical market for Korean exports of DOTP. We
14 believe that the Korean manufacturers export a majority of
15 their DOTP production. We believe that the Korean
16 producers have installed capacity for DOTP production that
17 is several times the size of the U.S. market or the Korean
18 market.

19 We have also -- as we have also described, the
20 rapidly growing for demand of DOTP in the U.S. has made our
21 market a target for their excess capacity using price as a
22 lever for competition.

23 This combination of overcapacity, increased U.S.
24 shipments and aggressively low prices has been detrimental
25 to our business.

1 The Korean producers have excess capacity beyond
2 their domestic demand for DOTP. We believe this excess
3 could more than blanket the U.S. market. Also, the U.S.
4 market is vulnerable to further serious injury because of
5 the years of declining price trends. The history of DOTP
6 imports to the U.S. market compels the conclusion that
7 these pricing trends will continue absent antidumping
8 relief.

9 One final point in closing. We have seen a
10 significant drop in profitability, despite the fact that
11 our volumes have increased. This happened because of the
12 dramatic drop in prices that resulted from import pricing
13 tactics.

14 We have had to sell more for less and the effect
15 has threatened the health of our business. For these
16 reasons, we ask the Commission to make an affirmative
17 finding that Eastman has been injured by the Korean imports
18 and faces ongoing threat of future injury as these trends
19 are set to continue.

20 We welcome the opportunity to answer your
21 questions. Thank you.

22 MR. O'BRIEN: Thank you. We will now hear from
23 Thomas Rogers of Capital Trade.

24 MR. ROGERS: Good morning. As Kevin said, I'm
25 Tom Rogers of Capital Trade. You just heard from the

1 industry witnesses -- experts on the product, the
2 company's results, market trends and the impact of
3 increasing imports on their business.

4 Nearly all -- because it's a single product or a
5 single producer industry, nearly all of the data in this
6 case is proprietary. So I'm just going to make some
7 general observations about the public record.

8 As you've heard, it's a commodity product, and
9 the basic framework through which the Commission should
10 evaluate the impact of imports on the domestic industry in
11 this case is that basis.

12 As the Commission knows from its experience in
13 many other cases, the key competitive feature of a
14 commodity market is that competition is based largely, if
15 not exclusively, on price. And that price-based
16 competition is the lens through which you should focus when
17 you do your analysis.

18 Now, it's through price that the Korean
19 exporters have gained their tremendous increases in
20 shipment volumes and market shares. It's through price
21 that the Korean product has captured sales from Eastman,
22 resulting in lower sales volumes to existing customers and
23 driving down prices across key accounts.

24 And it's the continually lower prices combined
25 with these surging volumes that have undermined Eastman's

1 profitability and pose an imminent threat of continued
2 injury.

3 I'll address these points in the slides that
4 we've handed out. First slide, subject import quantities.
5 This shows imports of Korean DOTP.

6 As you can see, for the HTS code 2917.39.2000,
7 and this is the category which Eastman believes that most,
8 if not all, imports of merchandise are entered, subject
9 imports more than doubled, from 12,300 short tons in 2013,
10 to more than 28,000 short tons in 2015.

11 Through the first five months of this year,
12 imports from Korea are up a further 6-1/2 percent as
13 compared to the year earlier period. So they keep going
14 up.

15 While nonsubject imports are present in the
16 market, their volume is down in 2015. They are sold at
17 higher prices, and they have been eclipsed by the surging
18 shipments from Korea.

19 Another source, the importer questionnaire
20 data that you are compiling will show a similar trend, but
21 regardless of the source, whether it's the questionnaires
22 or the data -- your census data, the record evidence is a
23 dramatic increase in imports, that's unambiguous.

24 While it's outside the Commission's normal
25 investigation period, it's also instructive to note that

1 Korean producers are not, as you've heard, they are not
2 traditional long-term market participants.

3 Eastman has been in this business for a long
4 time, the Koreans have not.

5 As shown in slide 2, you can see from zero
6 shipments in 2009, the Korean imports entered the market in
7 2010 and have increased sharply ever since.

8 Now, turning to demand, the company witnesses
9 described how demand for DOTP has been spurred by its
10 nontoxic profile. Demand has increased significantly
11 throughout the period, and so have the company's shipments.
12 Imports from Korea, however, have rocketed up at an even
13 greater rate. Korean producers obviously have been
14 determined to ramp up volumes and capture share.

15 U.S. shipment data are proprietary, so we will provide
16 further analysis of the share trends in our brief. But
17 suffice it to say, Eastman has lost significant share to
18 Korean DOTP over the past three-plus years.

19 Now, the large Korean volume and share increase
20 has been achieved through aggressive pricing. In the third
21 slide, this shows that the average unit value for Korean
22 DOTP has dropped precipitously from approximately 2000 --
23 and it's the red line in this chart, from approximately
24 \$2000 per short ton in January 2013, beginning in the third
25 period, to less than \$900 per short ton in May of 2016, the

1 last month for which data are available.

2 Clearly, there is significant price depression.
3 The chart also shows Korean exporters are price leaders,
4 and Korean DOTP is priced far below nonsubject imports.

5 And I might add that that price difference there
6 is far less than the 6-1/2 percent tariff cut that was
7 mentioned this morning, so that cannot be the explanatory
8 variable here.

9 As you've heard, Eastman has benefited from
10 lower raw material costs. However, the cost decline has
11 been overwhelmed by this Korean pricing.

12 The proprietary figures are masked, but in slide
13 4, we put together a bar chart which illustrates the sharp
14 rise in the company's COGS to net sales ratio. And this
15 is because the prices have fallen faster and farther than
16 the company's costs. And the questionnaire data that you
17 have will confirm this significant price suppression.

18 Now, looking again in a commodity market, you
19 would expect to see the prices of competing products moving
20 together. And assuming that all importers provide their
21 data fully and accurately, the ever-lower prices
22 of the Korean DOTP, we expect, will show significant
23 underselling.

24 And the direct impact of this underselling is
25 transmitted into the market through the numerous instances

1 of lost sales and lost revenue. As detailed in the
2 petition, low price competition from Korea has hit Eastman
3 across a range of its key accounts. And the impact of such
4 competition is direct, as many contracts have
5 meet-or-release provisions. Thus, each new Korean offer
6 puts downward price pressure on Eastman.

7 With respect to the specific pricing data
8 collected by the Commission, all Korean DOTP competes
9 against Eastman's product, whether it's product 1 or your
10 product 2. That is, the price of a 20-metric-ton truckload
11 of this commodity chemical impacts the price of the
12 identical product sold in bulk in a railcar and vice versa.

13 But regardless of how the pricing data are
14 examined, the big picture here is clear. Prices for DOTP
15 have fallen precipitously, and through their aggressive
16 pricing, the Korean producers have exported an increasing
17 volume of product to the United States.

18 Questionnaire data will show unambiguously that
19 the domestic industry has suffered material injury caused
20 by these ever lower-priced imports. Thank you.

21 MR. O'BRIEN: I'm Kevin O'Brien, I would now
22 like to summarize some of the reasons why we believe there
23 is a reasonable indication that the domestic industry is
24 materially injured or threatened by reason of imports of
25 DOTP from Korea.

1 The Commission defines the U.S. industry as the
2 producers as a whole of a domestic-like product and the
3 domestic-like product is the product which is like, or in
4 the absence of like, most similar in characteristics, with
5 the article subject to an investigation.

6 Eastman is the only U.S. producer of DOTP. The
7 product has the same chemical and physical characteristics
8 as the subject imports. It is interchangeable from a
9 customer perception and use standpoint. It is sold through
10 the same channels of distribution, to the same customers,
11 and it competes primarily on price.

12 DOTP is a commodity product, and while Eastman
13 has a strong brand and a reputation for quality and
14 service, Korean producers have -- are formidable suppliers
15 with very sophisticated supply chains, and U.S. purchasers
16 make their decisions on the basis of price.

17 The U.S. Customs data shows that the subject
18 imports enter through multiple ports of entry throughout
19 the United States and continually during the period of
20 investigation. These imports compete with Eastman's DOTP
21 in spiraling price declines throughout the United States.

22 Also, as shown in the Customs data, the average
23 unit value of the subject imports declined sharply from the
24 beginning of the POI to the end of the POI. This data is
25 consistent with the data mined data, which we also

1 submitted. The average unit price has dropped continually,
2 irrespective of the cost of raw materials.

3 To recap briefly some of the testimony,
4 conditions in the market took a turn for the worse when the
5 Korean producers grossly overbuilt their capacity and
6 targeted the United States for their unfairly priced
7 imports. While demand is increasing, Eastman could not
8 foresee the onslaught of Korean product beginning prior to
9 the POI but continuing throughout the POI and to the
10 present. Given the enormous Korean production capacity,
11 which we have included in our petition, there can be no
12 doubt that the Koreans are committed to directing their
13 exports to the United States.

14 I would also like to make a point about the lost
15 sales and revenue data which the Commission will be
16 reviewing. Eastman is confident that the data will show
17 repeated instances in which customers decided to go with
18 the low-priced commodity product from Korea. However, in a
19 larger sense, the low quotes go well beyond the specific
20 competitive situations. They destroy the U.S. market in
21 its entirety.

22 This is because when Eastman lowers a price to
23 meet one customer quote, it inevitably encourages an even
24 lower quote to the next customer by the Korean exporters.

25 With this dynamic, it is not long before lower

1 prices are pervasive throughout the U.S. market and a new
2 floor is reached, until the cycle repeats.

3 Under such conditions, it is almost impossible
4 to raise prices to virtually any customer.

5 The testimony earlier today was that Eastman
6 tried to put through a price increase effective April 1.
7 Not only was the price increase ineffective, prices
8 continued to decrease.

9 Another point which comes very clearly from the
10 petition is that the Korean producers are highly
11 export-oriented. The capacity put in place and the
12 production by Korean companies far exceeds any domestic
13 demand in Korea. The Korean producers are fully able to
14 execute on their plan to gain market share in the United
15 States.

16 I'd also like to say a few words about price
17 suppression.

18 Price suppression really takes two forms, one
19 when the U.S. price is being dragged down by lower import
20 pricing. The second is the inability to raise prices due
21 to the price floor that has been established.

22 So when the Commission considers whether there
23 is price suppression, the Commission, we believe, should
24 also take into account that while raw materials dropped
25 during the POI, raw material costs also increased during

1 the POI, yet you have not seen that reflected in pricing.
2 The pricing continues to decrease because of the inability
3 of Eastman to pass through any increase in price, given the
4 prevailing market conditions.

5 With respect to the pricing data, I'd like to
6 make two points. One that has been made previously that
7 product 1 and product 2, while they are being reported
8 separately, they compete against each other. Whether --
9 whether a supplier imports in a boatload of product or
10 imports in a smaller quantity, the end user is generally
11 interested in buying 20 metric ton quantities. And that's
12 the point of competition most of the time, and Eastman is
13 competing for those 20 metric ton quantities. Again,
14 regardless of how the product comes into the country.

15 The other point is the Commission has requested
16 quarterly pricing data, which is very commonly requested.
17 In this market, we are in such a situation that prices are
18 changing monthly. So quarterly pricing data can mask
19 competitive underpricing because, frankly, prices at the
20 beginning of the quarter are going to be dramatically
21 different than prices at the end of the quarter, because
22 prices have declined in the subsequent two months of the
23 three-month quarter.

24 As indicated in our petition, the adverse market
25 conditions have affected Eastman's capital investments.

1 Eastman had planned to expand its facilities, but those
2 plans have now been mothballed. There is no way under the
3 current circumstances that additional investments could be
4 justified.

5 I'd like to now turn to threat. Because we
6 believe that the record will show that Eastman faces an
7 imminent threat of material injury. In this regard, the
8 volume of imports is likely to increase. Imports are
9 increasing rapidly at the present time, and it's
10 interesting to note that of the monthly 2015 and
11 year-to-date 2016 data that was provided, two of the three
12 highest months are in 2016, namely February and April.

13 So the imports are not only increasing, but they
14 are -- the recent imports are even larger than the early
15 2015 volumes. So size and frequency are increasing.

16 Second, the volume of imports frankly will
17 increase because prices are continuing to dive. And as
18 prices get lower, frankly, the Korean producers are
19 encouraged to put more and more product into the U.S.
20 market.

21 And third, the Korean -- the subject producers
22 are export-oriented. These are multinational companies.
23 They have a very large overcapacity of product, and they
24 are very familiar with penetrating export markets.

25 We believe this is convincing proof of the

1 intention of these large multinationals to penetrate
2 further the U.S. market. There can be little doubt that
3 but for the present investigation, imports of the subject
4 product will inflict material injury to the domestic
5 industry in the imminent future.

6 That completes our statements. I would like to
7 reserve the remaining time for rebuttal.

8 MS. HAINES: Thank you very much. That was very
9 helpful. We appreciate you traveling all this way. Sorry
10 it's a little hot in D.C. these days.

11 We'll turn first to Ms. Martinez for questions.

12 MS. MARTINEZ: Good morning. Thank you for
13 being here today. Your testimony has been very helpful. I
14 have a few questions, and I apologize if it's a little
15 disorganized. I wanted to start with according to
16 Ms. Parker's testimony -- I just wanted to go into a little
17 bit more detail on the capacity expansions in your
18 Kingsport facility. What were those exactly, the timing of
19 those.

20 And for the acquisition of the Texas facility,
21 is DOTP the primary product that is produced there? When
22 did production of DOTP start there?

23 DR. CULLEN: I'll answer that question, Steve
24 Cullen from Eastman. With regard to the Kingsport
25 facility, that plant has existed and been manufacturing

1 DOTP for many years. However, we have on several occasions
2 executed different -- I would describe them as
3 debottlenecks, to progressively increase capacity, actually
4 in advance of growth in the market.

5 We use a 24-month forecasting period, so we're
6 looking ahead at what we believe our future supply is going
7 to need to be.

8 We could see from that process that we were
9 going to need additional capacity, which was why we -- when
10 we identified and then moved to acquire the Texas City
11 facility in advance of future needs for capacity, and then
12 restart that plant.

13 Basically, it was the fastest way that we could
14 add capacity in advance of when it was needed.

15 In response to the second question about Texas
16 City, the Texas City plasticizer plant only makes one
17 product, which is DOTP.

18 MS. MARTINEZ: When did that start production?

19 DR. CULLEN: It started production in April
20 2012.

21 MS. MARTINEZ: Thank you. Are there differences
22 in quality or other factors between the domestic product
23 and the product being produced abroad or the product being
24 imported?

25 DR. CULLEN: This is Steve Cullen from Eastman.

1 To our knowledge, no, there's not. The materials are
2 wholly interchangeable.

3 MS. MARTINEZ: And Mr. Cullen, you had mentioned
4 that no other products are made on the DOTP lines. In
5 theory, could there be? What would that entail? Have you
6 produced other products on those? Any additional detail
7 you could provide would be helpful.

8 DR. CULLEN: In regards to the plant in
9 Kingsport, Tennessee, that has made other products in the
10 past, several years ago. Certainly since my involvement in
11 the business, I would say from 2010, 2011 onwards, the
12 product has been wholly dedicated to the manufacture of
13 DOTP.

14 The Texas City assets, I think it was in the
15 testimony, originally made other plasticizer products,
16 phthalates basically. But we converted those specifically
17 for the manufacture of DOTP.

18 So could those units produce other products? In
19 theory, yes. That would take, depending on what product
20 you were looking at at the time, various amounts of
21 modification, capital investment and time, sometimes
22 significant amounts of time. It would depend exactly what
23 was involved, the extent of that.

24 Generally, converting a dedicated chemical plant
25 to the manufacture of another product is not a trivial

1 event. It's something we do as part of our business, but
2 you're talking generally about millions of dollars of
3 capital modification and significant amounts of time.

4 MR. YOBST: This is Brian Yobst, just one
5 clarifying point. I believe the last time we made another
6 product on the assets -- my understanding is the last time
7 we made another product on the assets in Kingsport that
8 currently produce DOTP was in or around 2012, fairly small
9 quantity.

10 MS. MARTINEZ: Thank you. Do you know if the
11 Koreans use the same manufacturing process as Eastman? Or
12 do you have any insights into that?

13 DR. CULLEN: This is Steve Cullen from Eastman
14 again.

15 My understanding is that Korean producers use
16 the direct esterification process, which is reacting terra
17 phthalic acid PTA with 2-EH, 2-ethylhexanol.

18 MS. MARTINEZ: So is there a reason why you
19 would prefer -- or do one process over the other? I'm just
20 trying to understand.

21 DR. CULLEN: Sure. In the case of, for example,
22 the Korean producers, I don't believe there is any DMT
23 produced in Korea. Certainly I don't think any of the
24 three producers we've mentioned today do manufacture DMT.

25 In the case of Eastman, we manufacture both DMT

1 and PTA, so we have the choice. And really, for historical
2 reasons and for operational convenience, we choose to use
3 the transesterification process. Actually, Eastman is one
4 of the few remaining producers of DMT globally. There's a
5 very limited number of producers. It's in single figures
6 globally.

7 MS. MARTINEZ: Thank you. That's helpful.

8 Just touching on the blends, is there a -- why
9 would an end user prefer to use a blend over DOTP? What
10 are those specific applications?

11 DR. CULLEN: This is Steve Cullen from Eastman.

12 I think, as I said in my testimony, the use of
13 blends generally is to aid the processing, and I'll give
14 you a couple of examples, as opposed to kind of modifying
15 the properties of the end material.

16 So, for example, you might add a specialty
17 plasticizer in small quantities with the main volume
18 general-purpose plasticizer to help the fusion, so that the
19 fusion of the PVC into the final article happens faster or
20 at lower temperature. That's one example.

21 A second example would be if the PVC product is
22 being applied as a liquid, which the industry term is
23 plastisol, you might add a specialty plasticizer to reduce
24 the viscosity of that plastisol that would allow it to be
25 processed in a more useful way.

1 But in both of those cases, and in most cases
2 certainly involving PVC, the main volume of plasticizer
3 that is used would be a general-purpose plasticizer.

4 MS. MARTINEZ: So you mentioned that the primary
5 market for these blends is Europe, but you would say
6 there's also a small market here in the U.S. for those
7 blends?

8 DR. CULLEN: Yes, both of those -- that is
9 correct, yes. We do -- the majority, vast majority of
10 volume that we sell as blends, does go to Europe for
11 specific applications there. We do sell a very small
12 quantity as blends in the U.S. And I think as we said, we
13 would describe that as de minimis. It's really a very,
14 very small proportion.

15 MS. MARTINEZ: Okay. Thank you.

16 Moving on to the import data, do you know what
17 products are coming in under the primary HTS number? I
18 understand that it's a basket category. Do you think that
19 most of what's coming in under that HTS is DOTP? And what
20 would the other products be?

21 MR. ROGERS: This is Tom Rogers. Just looking
22 at the data that we've seen, there are basically three
23 sources on the record. One is the DataWeb, which is the
24 2917 number. The second is from Datamyne, which is looking
25 at shipping manifest data. And that's data that the import

1 figures there were selected based on specific product
2 definition. So looking specifically for DOTP.

3 And then the third source of data, of course,
4 are your questionnaires.

5 We think there are some other products that
6 could be coming in under this basket category, but looking
7 at the figures and comparing the totals from the Datamyne
8 figures and from your questionnaire data, that's not so
9 clear.

10 So there -- the total volumes are in line with
11 each other, the trends are in line with each other. So it
12 seems to me, based on this evidence, that most of what's
13 coming in under that category would be subject product.

14 MS. MARTINEZ: And you're not aware of any
15 specific products other than DOTP that would be --

16 MR. ROGERS: No. We don't have the entry
17 information for that.

18 MS. MARTINEZ: So would you agree that
19 questionnaire data would provide the most accurate data set
20 for this investigation, in terms of imports?

21 MR. O'BRIEN: We think the Datamyne data is
22 highly relevant, because that is recorded by DOTP or --
23 DOTP comes in under another name as well.

24 But we know -- we know for a fact that that --
25 that those products are DOTP and are coming in.

1 So I think the questionnaire responses set a
2 floor, so you can be confident that at least the quantities
3 in the questionnaire responses are accurate. But we
4 believe that the numbers are actually higher, the actual
5 volume coming in, based on the Datamyne data.

6 MS. MARTINEZ: Thank you. So I'm just trying to
7 get a better sense of the timing. It was mentioned that
8 Korean imports weren't really in the market until around
9 2010. Can you comment on sort of the timing of the
10 Korea-U.S. free-trade agreement and those tariff
11 reductions, how did that play into it, and also the
12 environmental regulations, what was the timing of that and
13 how did that affect demand?

14 MR. YOBST: This is Brian Yobst. I can address
15 the question about increases in demand.

16 As we mentioned, a number of regulatory drivers
17 in our petition, in our comments today, have really
18 prompted brand owners to make decisions to choose to exit
19 phthalate use and switch over to nonphthalate use. And
20 that's the fundamental driver for the growth in the market.

21 As far as specific relationships with the
22 free-trade agreements, I can't really comment on that.

23 MR. O'BRIEN: We believe the effective date was
24 March of 2012, and that one of the effects was it had --
25 whether it was a primary effect or not, I think it's quite

1 clear that the perception was the U.S. market demand was
2 increasing.

3 And if you noticed that rest of world imports
4 are -- have decreased, in particular imports from China
5 have decreased. So what -- I think it is fair to say that
6 the free-trade agreement had an effect, but it had an
7 effect of displacing other imports that were coming in.

8 MR. ROGERS: This is Tom Rogers. I'd just like
9 to add that, you know, the free trade agreement, it was a
10 one-shot deal. It cut the rate at that point.

11 The imports have continued to come in at
12 ever-larger volumes, suggesting that, you know, that effect
13 is long gone and they're just continuing to pour product
14 in.

15 DR. CULLEN: This is Steve Cullen.

16 I think one other comment about that. If the
17 price effect was a function of the removal of duty under
18 the free-trade agreement, then you would have expected to
19 see a step down and then a flattening of price. And
20 clearly, that's not the case. The price has continuously
21 and progressively continued to decrease. So that's not a
22 function of the removal of duty.

23 MS. MARTINEZ: Thank you. That's helpful.

24 How do you respond to Respondents' argument that
25 demand sometimes exceeds production and so you need those

1 imports to meet the demand?

2 DR. CULLEN: As I think I said in response to
3 your earlier question, we have continuously increased our
4 capacity either by small debottlenecks at the existing
5 plant in Kingsport in advance of our forecast of what
6 future demand is going to be.

7 As I also mentioned, we use a 24-month ahead
8 rolling planning process called SNOP, to be able to predict
9 two years ahead what we think demand is going to be so that
10 we can then plan capacity with time to be able to respond
11 to that.

12 And part of that process, the outcome of that
13 was, you know, we identified a future need to increase
14 capacity, which we did by acquiring the Sterling Chemicals
15 company and the Texas City facility in 2011 and brought
16 that on stream in 2012.

17 And as you -- we've also testified, and you can
18 see from press releases, after bringing that on stream, we
19 then continued to expand in advance of demand by expanding
20 in 2014.

21 So what I would say is we have predicted the
22 growth in the market by identifying this switching and
23 technology shift, we call it, from phthalates, and
24 operationally have been projecting what demand would be and
25 adding capacity in advance of that consistently through --

1 actually the last eight years or so, and making
2 acquisitions in advance of that to meet that demand.

3 MR. O'BRIEN: I would only add that the
4 questionnaire response that we provided includes our
5 capacity data and also includes data that's directed to
6 exports.

7 And if you look at our capacity data, I think
8 it's pretty plain that we have the ability to serve the
9 U.S. market.

10 MS. MARTINEZ: Thank you. Looking at just
11 global export trends, I notice that Korea is more focused
12 on the Asian markets, such as China and Vietnam. Can you
13 comment on this? It seems like from your testimony that,
14 you know, you're saying that Korea is very focused on the
15 U.S. market. But it seems like a lot of their exports in
16 this category are still going to Asian markets.

17 DR. CULLEN: I don't quite know how to answer
18 the question. But yes, we look at statistics of exports
19 from Korea, where Korean producers choose to sell their
20 products is a -- is a matter for them. How they do that is
21 a different question. That's what we're here to answer
22 today.

23 But I think what it demonstrates is the excess
24 capacity that we've talked about that Korean producers have
25 over and above domestic demand, and the majority of their

1 production is being exported to whatever location that that
2 is.

3 What's clear is one of those destinations, and a
4 significant destination, is the United States. And the way
5 that that is being done is the -- is the impact on the
6 domestic market, which is the reason behind our petition.

7 MR. O'BRIEN: Yeah, I guess I would add the
8 following point. In addition to the very large capacity of
9 the Korean producers, who are in themselves very large
10 multinational companies, one of their markets had been
11 China. Frankly for products which end up in the United
12 States, flooring and other products. But the Chinese
13 chemical market has built its own capability over recent
14 years.

15 So while some -- there may still be some
16 increase in exports from Korea to China, there is quite a
17 bit of Chinese capability in its own right. So the Koreans
18 are left with a substantial overhang of capacity and a
19 Chinese market that simply cannot take it.

20 So hence, the U.S. market is seeing increasing
21 amounts.

22 MS. MARTINEZ: Thank you. I think I just have
23 one more question at this time.

24 So there was -- I saw a news release that BASF,
25 which is a U.S. importer, has plans to produce DOTP in

1 early 2017. How do you think this will affect the market?
2 Any insights? Or can you comment on that?

3 MR. O'BRIEN: I think we would like to comment
4 in the posthearing brief on that. We are extremely
5 reluctant to comment on another company's plans in terms of
6 how firm or unfirm they are, whether they will change,
7 whether they won't change. We'll be happy to take those
8 points up in the post-conference brief, if that's okay.

9 MS. MARTINEZ: Yeah, that's fine. Thank you.

10 MS. HAINES: Turn now to Mr. Clark.

11 MR. CLARK: Good morning. Again, I want to say
12 thank you for coming today to answer our questions.

13 I'd like to look a little bit at
14 substitutability. So there were traditional plasticizers
15 that were used. Some of those have been displaced because
16 of -- it sounds like primarily regulatory issues.

17 But there must be some other nonphthalate
18 plasticizers that are out there. How much does DOTP
19 compete with those? Could any of those be used on these
20 flooring applications, or do those go to different
21 applications?

22 DR. CULLEN: This is Steve Cullen from Eastman.

23 Yes, there are a number of different
24 plasticizers on the market. And we mentioned the
25 traditional ones being the phthalate, type of phthalate

1 chemistry.

2 Actually, I think the largest driver for the
3 growth of demand for DOTP or for nonphthalate alternatives
4 has been brand owner choice or consumer choice.

5 Regulation is actually, if you look at it fairly
6 narrow, around toy applications. But so yes, there are
7 other technologies, there are other plasticizers that would
8 fit into that nonphthalate category. However, to our
9 knowledge and belief, they're very, very minor market
10 uptake of those in the United States.

11 So as the replacement for the traditional
12 phthalate type in the applications that have chosen to do
13 that, DOTP has been, by far, the most successful.

14 MR. CLARK: What has made DOTP so much more
15 desirable? Is it cost? Is it because of some other
16 environmental concern or some other awareness of the
17 public? Is it just it's -- you know, its properties are
18 better suited to PVC or these particular applications?

19 DR. CULLEN: This is Steve Cullen.

20 I'll try and answer that. I think a number of
21 reasons -- I mean, these would be my opinion. But firstly,
22 it was readily available, so the product had been in
23 commerce in the U.S. since 1974, so I think was known to
24 people.

25 Eastman has invested many millions of dollars in

1 toxicity testing. So when you're looking to replace, you
2 know, a traditional phthalate product, because of the
3 controversy around its toxicological profile, and we could
4 spend all day debating that, it's quite a debatable
5 subject, but we were able to provide data because of the
6 investments that we've made to show that its toxicological
7 profile was comprehensive and also was clean, so there was
8 no kind of question marks.

9 So when you're making a substitution from a
10 product where there are question marks, you want to go to
11 one where there are no question marks. And we had the data
12 available to be able to do that.

13 In addition, availability was a question.
14 Market needed to be available in sufficient quantities at
15 the time that people wanted to shift. We had existing
16 capacity already in place with room to grow, and then as
17 I've also said, we've been adding to that capacity in
18 advance of the increasing demand.

19 From a performance point of view, it's, you
20 know, a good replacement for the traditional phthalates.

21 So I see a number of different reasons that
22 contribute to that. Other products were either an offer in
23 the market or, you know, available that maybe didn't have
24 all of those profiles. And I think it's the combination of
25 those factors that has meant that of all the options that

1 were out there, DOTP has been the one that has been the
2 most successful.

3 I say that that's not only true in the U.S.,
4 actually, that's been true on a global basis, in the --
5 where people have required -- or wanted to replace
6 traditional phthalates with an alternative DOTP on the
7 global basis has been the one that has been chosen. And I
8 think that also explains why excess capacity has been, you
9 know, developed in other markets such as Korea.

10 MR. CLARK: Thank you. When did -- so Sterling
11 shut down their plant in 2010, and you purchased their
12 facility in 2011 in anticipation of some of the changes
13 that were enacted in 2012. Again, was that -- was that
14 looking at regulations such that you anticipated the
15 increase in demand so you -- how far in advance was that
16 known, so that you were able to make those -- I mean, was
17 that part of your planning for the increased DOTP or again
18 was that just an awareness of where the public was going,
19 where demand was going to be?

20 DR. CULLEN: This is Steve Cullen.

21 Really, the -- so yes, you're correct, the
22 plasticizer plant of Sterling Chemical was announced was
23 closing down at the end of 2010. So at that point looking
24 forward, I was involved in the strategy work at that time
25 in trying to predict how far is this conversion going to go

1 and what capacities or demand do we see in the market?

2 So projecting forward as to what capacities we
3 thought we might need to supply demand in the U.S. market
4 meant that Sterling Chemical was a good fit for us.

5 You mentioned about changes in 2012. I think
6 the only change we've mentioned today in 2012 was the free
7 trade agreement between the U.S. and Korea. Really, the
8 acquisition had nothing to do with that. It was adding
9 capacity at the right time that was suitable for what we
10 needed to do in advance of the market needing that capacity
11 online.

12 MR. CLARK: You're right, I'm sorry about that.
13 I had 2012 in my mind and because of the rest of the
14 timing, I just put the two together, sorry.

15 So I just want to ask about -- you're saying
16 regulations aren't really driving this, it's pretty much
17 just demand and what customers want. But you did mention
18 that California had some issues with some of the products
19 on its Proposition 65.

20 What is going to happen now as a result of the
21 new TSCA, the Toxic Substances Control Act, and how is that
22 going to hopefully try to unify things across states and it
23 will be uniform for federal regulations?

24 DR. CULLEN: This is Steve Cullen.

25 This would be purely my opinion. I guess nobody

1 really knows. But in my opinion, the switch from -- of
2 brand owners, brand owners who are selling consumer
3 products, generally products that have a fairly high human
4 contact, has really increased the use of nonphthalate
5 plasticizers to the point I don't think -- I don't think we
6 can see people going back.

7 So Proposition 65 refers only to California. It
8 means that any article that's sold in the state has to
9 carry a label that it may contain a product known to the
10 state to have some adverse health effects. That in itself
11 I think is a driver why a brand owner who makes a great
12 consumer product that they love to sell into the market
13 doesn't want a label on it saying it's got something bad in
14 there.

15 The science of that is debatable, and widely
16 debatable, no need to get into that.

17 So I think that's really the driver, with the
18 new TSCA regulation preempting some of the state
19 situations, will that have an impact? I don't know. I
20 think the consumer trend personally is that brand owners
21 just want to get away from the controversy and get back to
22 what they're good at, which is selling their branded
23 consumer goods to people and moving on. And I think things
24 will move on from that.

25 MR. O'BRIEN: If I could just add, Mr. Yobst

1 mentioned during his testimony that Home Depot and Lumber
2 Liquidators just came out with an instruction that they
3 don't want any phthalates in their flooring products. And
4 that's without regard to any particular piece of
5 legislation. But it will surely -- it and actions like
6 that will drive demand foundationally.

7 MR. CLARK: Okay. Thank you.

8 I guess I'd like to look a little bit at just
9 some of the raw material issues. You talked about how your
10 raw material costs have gone down. Other than the input of
11 oil, what else is going to drive raw material costs? What
12 is going to affect any of your availability or your
13 competitors' availability for raw materials?

14 MR. CULLEN: I can answer that. I guess there
15 were two sets of questions in there. One was around what
16 drives the cost of those raw materials.

17 I think if you think of the DOTP molecule in two
18 parts, two halves, there is the part that's made either
19 from terephthalic acid or from our case, DMT and then
20 there's the 2-ethylhexanol part.

21 The DMT or PTA part is a petrochemical
22 derivative, so the raw material is paraxylene, which is a
23 by-product from oil refining, so is directly linked and
24 driven with oil price. Although it has its own market, so
25 its own market is subject to supply demand in the same way

1 as any derivative.

2 So that's on the PTA/DMT side. On the
3 2-ethylhexanol, the main input there is propylene, which is
4 -- either comes from by-products of oil refining or from
5 cracking, naphtha or shale gas.

6 And increasingly also from being produced on
7 purpose.

8 The other input would be basically they call sin
9 gas, which comes from natural gas. So the price drivers
10 for oxyl alcohol would be propylene and natural gas, and
11 each of those has their own market as well which will move
12 with supply and demand.

13 In terms of availability of those materials,
14 they're basic petrochemicals. And generally they're
15 available in the millions of tons as opposed to the
16 thousands or hundreds of thousands of tons that we're
17 talking here in the plasticizer, plasticizer arena.

18 MR. CLARK: And so the availability for both
19 processes would basically be the same, you're basically
20 giving derivatives from oil for both the processes. So any
21 impact that there would be for Eastman would also affect
22 your competitors; is that correct?

23 DR. CULLEN: We produce in the U.S. so if
24 there -- the availability supply demand dynamics, if there
25 was something in specific to the U.S., it would be specific

1 to us, that doesn't happen very often.

2 Producers in Asia, for example, would be subject
3 to the dynamics in Asia and the availability in Asia. But
4 generally, these are very, very broadly traded commodities,
5 petrochemical commodities, in both those regions produced
6 in millions of tons, very basic materials.

7 MR. CLARK: Okay. Thank you. I'm trying to
8 look at some of the pricing issues.

9 How much does volume impact the pricing? One of
10 your comments was it doesn't really matter anymore because
11 everybody is so aware of what the import prices are. And
12 yet I'm sure if you're going to sell somebody, you know, a
13 small container of DOTP, you're going to sell it at a price
14 premium just because packaging is suddenly so much more
15 expensive relative to the product.

16 MR. YOBST: Brian Yobst. I'll take that
17 question.

18 As was mentioned, DOTP in the U.S. is typically
19 moved from producers to consumers in approximately 20 metric
20 ton units. Tank trucks would be Eastman's typical mode of
21 shipment to our customers. We also have railcars.

22 Most users of any scale are purchasing at a
23 minimum of a full truckload quantity. So that 20 ton -- or
24 20 metric ton, container size that was mentioned earlier is
25 sort of the standard of the industry.

1 So when we look at customers, most of Eastman's
2 customers for plasticizers for DOTP would either be buying
3 trucks, quantities, 20 metric tons, or a small segment buying
4 80 metric ton railcar quantities. Smaller quantities than a
5 full truckload would be packaged goods and they tend to be
6 handled by Eastman through our distributor channel.

7 So typically, customers, whether a medium-sized
8 customer or a very large customer, is buying in 20 metric ton
9 units.

10 The question you asked is how does pricing vary.
11 Well, I believe, as the market has been more inundated by the Korean
12 pricing, any differentials between customers size-wise and
13 consumer size-wise, they greatly diminished over the period
14 of inquiry here.

15 From our perspective, and this would be an
16 opinion, when importers bring in a 20 metric ton quantity,
17 they're really not as concerned with the size of the
18 customer. They tend to put pricing in a narrower range
19 than we have seen historically.

20 So I believe largely the price premium
21 differentials for small customers versus large customers
22 are smaller than they have been prior to this period.

23 MR. CLARK: You just said that some of your --
24 some of your sales through your distributors would be
25 perhaps in different sizes. Would that -- I guess would

1 those be for specialty applications? Would that be
2 anything that's of greater concern, whether it's, I don't
3 know, in the medical industry or, you know? We're talking
4 about toys of course, but toys have got to be huge volumes.
5 I'm not sure what -- how extensive the stuff would be in
6 other applications.

7 I'm just wondering, what would be these smaller
8 purchases and is that, again, something that's unique?

9 MR. YOBST: Typically, as I mentioned, small
10 purchases, package quantities, are typically handled
11 through our distributors. So they are the supplier to
12 those end users. We don't have good visibility into where
13 those products go because our competitor -- I should say
14 our distributors downstream from us.

15 But typically, those folks are handling smaller
16 quantities for the small user, who wouldn't typically buy
17 the full 20 metric ton container.

18 But as we have noted in our petition, under
19 confidential information, the share of our distributors is
20 noted there, and I think that was the perspective in where
21 it's at.

22 MR. CLARK: Thank you. If somebody wanted to go
23 back and forth between the Korean and Eastman's DOTP, would
24 there be anything that would prevent them from doing that?
25 Is there any concern about the product not being the same?

1 Is there any concern about mixing of the product, anything
2 along those lines, that would prevent somebody from
3 switching back and forth and saying today I'm getting a
4 cheaper price from you, I'll buy it from you, yesterday I
5 got it from them because they offered the best price.

6 MR. YOBST: Brian Yobst. I'll take that.

7 Based on the examples we have provided in the
8 petition, we have identified a number of customers that buy
9 both Eastman product and Korean product based on price. So
10 we can only presume -- only can presume they're using them
11 interchangeably.

12 MR. CLARK: Thank you.

13 MR. YOBST: How they manage their inventories,
14 you'd have to ask the customer.

15 MR. CLARK: Is there any difference in
16 geographical sales that you've been able to identify? I am
17 sure that Eastman sells pretty much nationally, and you
18 mentioned before that the Korean imports come into multiple
19 ports. But is there a preference? Since Eastman is in
20 Texas and Tennessee and Korea is on the Pacific, it would
21 seem like the West Coast would tend to buy more Korean than
22 the East Coast would.

23 DR. CULLEN: This is Steve Cullen.

24 I would say that the material is ubiquitous. It's
25 available readily in all regions of the U.S.

1 MR. CLARK: Okay. Thanks. How important are
2 lead times to some of your purchasers? Does that -- is
3 that something that's going to affect whether they're going
4 to buy from you as opposed to somebody from Korean imports,
5 or is there enough inventory in the U.S. that it's just
6 about shipping from wherever it is in the U.S. anyway, it's
7 not about having it made to order in Korea and then shipped
8 across the ocean?

9 MR. YOBST: This is Brian Yobst.

10 Eastman's understanding would be that there is
11 significant quantities of DOTP imported from Korea stored
12 in the U.S. and made available to the U.S. market. There's
13 also another segment that's imported directly. So from
14 that perspective, the material is available in similar
15 transit as Eastman's product.

16 MR. CLARK: Okay. Thank you. As far as just
17 general availability of the product, do you -- do you want
18 to try to maintain your plant operating continuously, so
19 you produce to put it in inventory and sell things from
20 inventory, you don't make things to order? Is that the
21 easiest way to -- you operate your plant continuously and
22 then you shut it down I guess so that you're away from your
23 business cycle, your seasonality? You said March through
24 October is when there's the greatest demand because of the
25 construction industry. So would you do your maintenance

1 during whatever, late fall, Christmastime and just try to
2 produce as much as you can, to put it in inventory?

3 MR. YOBST: Actually, I think as Steve Cullen
4 mentioned, plasticizer business uses a 24-month planning
5 cycle, so we anticipate our customers' demand, forecast
6 their demand, and produce to that forecasted demand.
7 Taking into account any planned outages for maintenance or
8 other issues.

9 So we really fundamentally produce to forecasted
10 demand.

11 MR. CLARK: Okay. Thank you. Just trying to
12 look through my notes here and see if I have any other
13 questions that I haven't addressed so far. I think I'll
14 stop for now. Thank you for your answers.

15 MS. HAINES: Thank you. We'll turn to
16 Ms. Dempsey now.

17 MS. DEMPSEY: Like my colleagues, I also wanted
18 to thank you all for coming to testify before the
19 Commission. Your testimony has been very helpful. I don't
20 have many questions. I want to start off asking, several
21 of you have testified that DOTP competes primarily on the
22 basis of price. But are there any nonprice factors that go
23 into customers' purchasing decisions? And how important
24 are those nonprice factors?

25 DR. CULLEN: This is Steve Cullen. I'll try and

1 answer those. To be honest, I would say we've tried to
2 increase the number of nonprice factors that we are able to
3 provide other sources of value to our customers. And I
4 wish we'd been more successful than we have.

5 For example, we branded the product, we actually
6 sell it under a brand name Eastman 168. But DOTP is so
7 ubiquitously available in the U.S. market, all customers,
8 the whole market refers to it by its generic name, DOTP.

9 So we would look at trying -- other value adding
10 services that we are able to provide.

11 For example, we have very significant
12 capabilities and know-how in technical service. So when
13 you're converting from the use of a traditional phthalate
14 product to DOTP, hopefully Eastman 168 but DOTP, that
15 requires sometimes some reformulation. So we have some
16 capability in being able to know how to do that and help
17 our customers do that.

18 An example of what we see is that we find, in my
19 belief, we have a very high market share in those first
20 conversions, because people need our help. I think our
21 stature, our reputation, knowledge in the market,
22 encourages people to work with us during that phase.

23 Then once they get back to routine, where
24 they're making their consumer product, just now it's
25 nonphthalate as opposed to phthalate, then the supply

1 totally commoditizes, and those nonprice factors become
2 largely irrelevant and it does come down wholly to price.

3 MS. DEMPSEY: Following up on that, in any of
4 your lost sales or revenue allegations with respect to
5 purchasers, did purchasers ever give you any nonprice
6 reasons that they decided to go with the Korean product?

7 DR. CULLEN: Brian, if he could answer that,
8 having been the business manager through that phase.

9 MR. YOBST: About the only comment I would say
10 at a very high level is some purchasers would desire to
11 have multiple suppliers, so that's, as I'm in procurement
12 now, that's actually, you know, a choice to -- for the
13 purchaser.

14 So dual supply is a reason for customers to
15 choose to buy product from folks other than Eastman.

16 DR. CULLEN: Actually, going back to those
17 nonprice factors, a significant reason behind our
18 acquisition of the Texas City site was that we would then
19 have two manufacturing plants on different site locations
20 to make the same product.

21 So from a supply security point of view, we felt
22 that that was very important in -- for us to do as the
23 original supplier.

24 So we could have chosen to have built a new
25 plant in Kingsport next to the existing plant, but we felt

1 that actually having a second one on a different site, in a
2 different state, was very important from a strategic supply
3 security point of view.

4 MR. O'BRIEN: I would only add that on the issue
5 of more than one supplier, while that may be a preference
6 for a customer, whether or not the ratio is 90 to 10 or
7 something less than that, is going to be driven by price.

8 In other words, the customer may want the
9 security of having a second source, but that by no means
10 means the supply will be split. It will be very heavily
11 toward the lowest price supplier, with the other one just
12 as a safety valve.

13 With respect to Dr. Cullen's point just now, it
14 is important to recognize the sophistication of the Korean
15 producers. These are world class, multinational, very
16 sophisticated companies that have their supply chains into
17 the United States very well established.

18 So Eastman has two producing locations in the
19 United States, that's nice. But it only goes so far.
20 These are very -- frankly, very, very formidable Korean
21 producers as well.

22 MS. DEMPSEY: Thank you. I just have one more
23 question with respect to nonsubject imports on the market.
24 I know you said their share has decreased during the period
25 of investigation.

1 I just want to hear what your thoughts are on
2 nonsubject imports' impact on the market and whether DOTP
3 from those nonsubject countries are readily interchangeable
4 with the subject imports and the domestic like product.

5 MR. ROGERS: Well, I think the question of
6 interchangeability is for the company to discuss, but DOTP
7 is a commodity product, so I think that's been established.

8 With respect to the volume of nonsubject, just
9 looking at the data, it appears that they have been
10 squeezed out. I think the bulk is coming from Canada and
11 Mexico and if you look at the import data, you see those
12 volumes going down.

13 So in my mind looking at the data, I see them
14 being squeezed out by the Korean imports.

15 MR. O'BRIEN: And the point that I would make is
16 that Mr. Rogers showed -- prepared a chart showing the
17 pricing of the subject imports versus the nonsubject
18 imports, and that I think tells a very important story that
19 the nonsubject imports are simply not causing the damage.

20 MS. DEMPSEY: Thank you. And to follow up, one
21 last thing, you mentioned that it is the nonsubject import
22 pricing which is above that of subject import pricing is
23 not solely due to the Free Trade Agreement. Is that
24 accurate?

25 MR. ROGERS: Just looking at the absolute

1 difference in the pricing, it's certainly more than 6-1/2
2 percent tariff. So that is not the explanatory variable
3 there for that spread. The gap is significant, and the
4 Korean pricing is much lower than the nonsubject imports,
5 looking at that over time.

6 And you also see that that spread is growing.
7 So tariff cut was a few years ago, but the spread between
8 the Korean pricing and the nonsubject pricing is higher, or
9 the Korean price is dropping faster, shall we say.

10 MS. DEMPSEY: Thank you. I have no other
11 questions. Thank you.

12 MS. HAINES: Turn to Mr. Yost.

13 MR. YOST: Good morning. I join with my
14 co-workers and colleagues in welcoming you here this
15 morning. It's still morning.

16 I have a couple of questions, and getting back
17 to demand, which I know we've kind of beaten to death this
18 morning.

19 But if I take from your statements on the
20 regulatory and consumer preference factors, demand for
21 non-ortho phthalates is growing. Is that uniform across
22 the spectrum of non-ortho phthalates? Or is it
23 particularly affecting DOTP?

24 DR. CULLEN: This is Steve Cullen. I think it
25 particularly has been the case with DOTP. So of the

1 different flavors, if you like, of nonphthalates that are
2 available, DOTP has been the most successful at replacing
3 the phthalates. It's been the product of choice, if you
4 want to call it that.

5 MR. YOST: So if I look at Eastman's list of
6 nonphthalic plasticizers, you know, and it has fairly
7 extensive list of I don't know 30 or so items, you would
8 say that the Eastman S 168, which is the subject product
9 here, is growing the fastest or growing the most in
10 relation to other plasticizers?

11 DR. CULLEN: This is Steve Cullen again.

12 I think you need to consider that we tried to
13 outline, there were two classes of plasticizer, if you
14 like. So the first one being the general purpose
15 plasticizers.

16 Those are the largest volume materials and
17 generally commodities.

18 MR. YOST: And that would include DOTP?

19 DR. CULLEN: DOTP would fall into that category.
20 So those are used in the largest proportion in an article.
21 In many cases, actually is the sole plasticizer. So the
22 volumes involved there generally will tend to be the
23 largest.

24 The other materials on our list, we don't have
25 any other nonphthalate general purpose plasticizer products

1 in our portfolio. The other 29 or whatever that number is
2 that you mentioned really would fall into the specialty
3 category.

4 So in the specialty category, a similar scenario
5 is playing out that traditional phthalate specialty
6 plasticizers are being replaced, and that's why we have
7 those products in our portfolio. But that's really not
8 part of the subject discussion today.

9 Q So in your sales, DOTP is by far the greatest --
10 the greatest single sale of this list?

11 DR. CULLEN: Yes, it's our largest product
12 today.

13 MR. YOST: I see. Then on the question of raw
14 materials, I notice, Mr. Cullen, you mention that Eastman
15 is one of the -- one of the last DMT, dimethyl
16 terephthalate, producers in the U.S. How about the
17 Koreans? If I understood you correctly, they don't use DMT
18 in the -- in their process?

19 DR. CULLEN: The first part of your question is
20 correct, yes, we're the last producer of DMT in the U.S.

21 My understanding of the companies we mentioned,
22 LG Chem, Aekyung and Hanwha, I believe are all using the
23 direct esterification process based on TPA.

24 I think I may have said DMT was not available in
25 Korea. I'm not sure if that is actually true. I would

1 have to check and come back on that.

2 But my belief is the Korean producers do not use
3 the transesterification process.

4 MR. YOST: Okay. Are there public -- are there
5 publicly available price indices for these three inputs,
6 TPA, DMT and 2 EH?

7 DR. CULLEN: There are trade data companies who
8 provide service that you can buy that would give pricing
9 indexes.

10 I guess they're publicly accessible, but you
11 have to pay to get them. Companies like ISIS or IHS or
12 there's other market -- market services that do report on
13 those -- on those types of industries.

14 MR. YOST: Then post-conference, if you have
15 those available, would you please submit them
16 confidentially?

17 DR. CULLEN: Do you mean the actual data or
18 the -- or the names of those kind of providers?

19 MR. YOST: The actual data.

20 DR. CULLEN: Okay. There is maybe some
21 confidentiality -- I'm sorry, copyright questions that we'd
22 have to address, but we can look into that after the
23 conference.

24 MR. O'BRIEN: Sure.

25 MR. YOST: Okay. Okay. Then I think Mr. Rogers

1 referred to the ratio of sales to cost is increasing. With
2 the testimony being that raw materials have decreased, then
3 the most obvious category that increased would be our
4 category of other factory costs.

5 Would you please submit post conference the
6 categories and the increasing costs, in that particular
7 category.

8 MR. O'BRIEN: Certainly, we'll do that.

9 MR. ROGERS: This is Tom Rogers. I think also
10 the -- we can certainly provide the cost breakdown. But I
11 think the reason -- the main reason for the change in the
12 ratio is the fact that the prices have declined so
13 dramatically. The end price, the selling price of the
14 product?

15 MR. YOST: Okay. One final question. I notice
16 also in Eastman's product list that there's a product
17 called 168 SG. Does that differ in any significant degree
18 from 168 to the DOTP, or is it included in the subject
19 product.

20 MR. O'BRIEN: It is included in the subject
21 product. It is DOTP, yes.

22 We would prefer to address it in the
23 post-conference brief, in terms of the actual difference.
24 But it's DOTP.

25 MR. YOST: That's fine. Thank you very much.

1 That concludes my questions.

2 MS. HAINES: Thanks. I have just one question.

3 In the opening statement for the Respondents, they were
4 talking about, as you said, their preference to have
5 multiple suppliers in case of shortages. Was there any
6 time during the period of investigation where you were
7 unable to meet demand? A purchase request?

8 DR. CULLEN: Hopefully, I tried to address that
9 during my comments that no, during the period we're talking
10 about here, there's not been a case where we've been unable
11 to supply because demand is exceeding our capacity.

12 MS. HAINES: That's all I had. Thank you very
13 much. This was extremely helpful. We appreciate you
14 traveling all this way.

15 MR. O'BRIEN: Thank you.

16 DR. CULLEN: Thank you.

17 MS. BELL: Will Respondents please come forward.

18 MS. BURR: Thank you. And just a note of
19 introduction. The information that Mr. Ted Fisher will
20 provide, who is the director of sales and marketing for
21 ALAC, importer of DOTP from Korea, we have taken much of
22 the information provided for based on the experience of the
23 company and what was provided to us in the petition by
24 Eastman, the public version of the petition.

25 So I would just like to note that for the panel.

1 With that, Mr. Ted Fisher.

2 MR. FISHER: Good morning. My name is Ted
3 Fisher. I am the director of sales and marketing for ALAC
4 International. I want to thank the ITC for the opportunity
5 to participate in this conference and concerning the
6 preliminary antidumping investigation for DOTP from Korea.

7 I've worked in the vinyl industry for 21 years,
8 16 years in a small manufacturing company as a plant
9 manager and a general manager, purchasing raw materials and
10 processing them into finished goods, and five years on the
11 supply side, supplying raw materials to ALAC's diverse
12 range of customers.

13 ALAC International is an importer of chemicals
14 and chemical products founded in 2004 headquartered in New
15 York, New York, has 15 employees and is a certified
16 minority supplier to approximately 100 customers that range
17 in size from small family-run businesses to global
18 multinational firms.

19 ALAC imports DOTP and DIMP from Korea and our
20 primary supplier is Aekyung Petrochemical. Among the U.S.
21 distributors, ALAC is unique in both its shore terminal
22 positions that allow us to provide truckload quantities on
23 short lead time of both DIMP and DOTP.

24 We understand the Petitioner, Eastman Chemical,
25 is claiming there has been an increase in the amount of

1 DOTP imports from Korea and that those imports are causing
2 material injury to the sole producer in the United States.

3 The plasticizer market in the United States is
4 much more complicated than portrayed by Eastman in its
5 petition, and the conditions of competition have been
6 impacted by a number of factor related to demand, cost of
7 production, shortages and transportation costs. I'd like
8 to address each of these in turn, please.

9 The plasticizer market is global, ever evolving
10 and highly competitive. One of the primary general purpose
11 plasticizers in the U.S. is DIMP produced in the U.S. by
12 Exxon. DIMP dominated the plasticizer market in the United
13 States for several years, up until increased regulatory
14 pressures as noted earlier with the 2013 listing of DIMP on
15 California Proposition 65, and the 2014 regulatory
16 requirement for products sold in the state of California
17 containing DIMP, to have a toxic warning label.

18 Even with these regulatory pressures, DIMP is
19 still the dominant general purpose plasticizer in the
20 United States. These regulatory pressures, however,
21 increased demand for DOTP, and Eastman became the largest
22 and according to its petition the sole U.S. producer of
23 DOTP. Eastman is the dominant supplier of DOTP in the
24 United States and is certainly benefiting from the shift
25 from DIMP to DOTP.

1 In fact, Eastman expressly addressed this issue
2 in its 2015 annual report that was attached to its
3 petition. Eastman reported the plasticizer product line is
4 expected to benefit from the recovery in the North American
5 building and construction industry and the shift in vinyl
6 flooring production to the United States from Asia Pacific.
7 So Eastman sees its plasticizer business on the cusp of
8 expanding, not decreasing as it alleges in its petition.

9 It should also be noted that plasticizers are
10 evolving as chemistry and technology evolves. And market
11 pressures to make products more environmentally friendly.
12 The next generation of plasticizers is likely to be
13 biobased, made from more environmentally friendly products,
14 safer for consumers and the environment. It is only a
15 matter of time and the speed of technology that will
16 determine the time for the next generation of plasticizers
17 to take the preeminent position in the marketplace.

18 Plasticizer market is very competitive, and as
19 production increases in the United States, without a
20 corresponding increase in demand, the price decreases.
21 Eastman noted in its 2015 annual report that some products
22 are sensitive to periods of supply and demand imbalance,
23 either when incremental capacity additions are not offset
24 by corresponding increases in demand, or when demand
25 exceeds existing supply.

1 Eastman is currently the sole U.S. producer of
2 DOTP, and its production capacity is very large. But as it
3 admits in its annual report, there are times when demand
4 exceeds existing supply.

5 This can be a common occurrence in the
6 plasticizer market and is one of the reasons that our
7 buyers have multiple suppliers of plasticizer, so when
8 demand is very high, they have the ability to use other
9 sources.

10 In this respect, DOTP imports play a fairly
11 small role in the overall market for plasticizers, but the
12 increased imports simply correlate to the increased demand
13 for DOTP in the United States.

14 It's also important to note that as the sole
15 U.S. producer of DOTP, Eastman not only leads in the
16 production of the product, but is also setting the price
17 for DOTP on a monthly basis. The import prices may
18 fluctuate a bit, because of the time lag on when the import
19 price is agreed to and when it actually reaches the U.S.
20 market, the price for imported DOTP is negotiated by the
21 importer and set approximately three months before it
22 enters the U.S. market.

23 So if the market forces that impact the price
24 during that period, the importer must endure those
25 fluctuations. On average, it takes 45 to 75 days for DOTP

1 in bulk to reach the East Coast of the U.S. from Korea.

2 There have been new developments that have
3 impacted both DOTP production and price. The first, as
4 mentioned earlier, is the implementation of the U.S.-Korea
5 Free Trade Agreement, and the reduction of tariff from 6.5
6 percent to zero in 2012.

7 Second, as mentioned earlier, oil prices have
8 dropped to their lowest level in many years, and this led
9 to lower DOTP production costs. These factors made DOTP
10 imports from Korea less expensive at a time when DOTP in
11 the United States was increasing.

12 In Eastman's annual report, it highlights that
13 its adhesives and plasticizers product line had sales
14 revenue of \$1.2 billion, accounting for 12 percent of
15 Eastman's total sales.

16 As the sole U.S. producer and largest supplier
17 of DOTP in the United States, it is absurd for Eastman to
18 claim that the small amount of imports from Korea are
19 setting prices in the U.S. DOTP market. I would therefore
20 disagree with the statement in their petition claiming that
21 it has experienced material injury in the form of
22 significant loss of profits, decline in market share, drop
23 in prices and wages and lost sales.

24 In 2014, Eastman announced that it was expanding
25 its capacity to produce DOTP in the United States,

1 increasing its production capacity to 200,000 tons.
2 Eastman included the following language in its 2015 annual
3 report. "Increase in the relative use of nonphthalate,
4 rather than phthalate, plasticizers in the United States,
5 Canada and Europe has accelerated and is expected to
6 continue to increase more than general economic growth due
7 to the increasing regulatory requirements and consumer
8 preferences. In addition, the plasticizer product line is
9 expected to benefit from the recovery in the North American
10 building construction industry and the shift of flooring
11 production to the United States from Asia Pacific."

12 Another major producer, as mentioned earlier, of
13 plasticizers, BASF, announced in October 2015 that it
14 planned to convert existing production capacity in Texas of
15 DIMP and DPHP over to DOTP. Such expansion in DOTP
16 production is inconsistent with Eastman's claims of
17 material injury due to lost sales, lower average unit value
18 and decreasing market share in the United States due to
19 imports from Korea.

20 The recovery in the building and construction
21 industry is taking place but perhaps not as quickly as
22 Eastman anticipated. In the relocation of the vinyl
23 flooring production has similarly taking longer to
24 materialize than first expected.

25 It is more likely that these factors that have

1 adversely affected demand have caused the alleged negative
2 impact or material injury to Eastman's plasticizer business
3 than have imports from Korea.

4 In addition, Eastman is moving its plasticizer
5 line to a newly created chemical and intermediates segment
6 of the company, according to its annual report, combining
7 plasticizers and chemical intermediates into the same
8 segment will better optimize the oxo stream and benefit the
9 overall -- the company overall.

10 It is not clear if this adjustment caused any
11 disruptions for the plasticizer business that should be
12 considered.

13 I have explained that the DOTP market is complex
14 and can experience fluctuations based on demand,
15 availability, supply, quality of supply, input of
16 production costs, as well as transportation costs.

17 Over the last few years, all of these factors
18 have come into play with an increase in the demand for DOTP
19 in the United States and a dramatic decrease in the cost of
20 production and transportation costs. Imports of DOTP from
21 Korea have increased over the last few years, and the
22 reasons are very clear.

23 Korean companies produce a high quality DOTP and
24 work to ensure there is a sustainable supply of product.
25 As production costs decreased, so did the cost of

1 production and with KorUS coming into force, removing the
2 significant 6.5 percent tariff, Korea became more
3 attractive as a supplier.

4 To the extent that Eastman is claiming that it
5 has experienced any problems in its DOTP business, it may
6 be more accurately attributed to Eastman's market
7 projections and announced production expansion, rather than
8 increases of DOTP imported from Korea. Thank you.

9 MS. BURR: Happy to take any questions.

10 MS. HAINES: Thank you very much.

11 Ms. Martinez.

12 MS. MARTINEZ: Good morning. Thank you for your
13 testimony. As a preliminary matter, do you agree with the
14 petitioner's domestic like product definition.

15 MS. BURR: I think at this point we would like
16 to address that in the post-conference brief. We think
17 that the petition is what it is. We do note that it is a
18 heavily competitive market and that there is some
19 interchangeability in the products. But we have not
20 addressed that in our testimony today.

21 MS. MARTINEZ: That's fine, thank you. I guess
22 I'm just trying to make sense of -- you mentioned that
23 perhaps Eastman overprojected maybe, and due to capacity
24 expansions -- I guess I'm just trying to understand your
25 argument a little bit better.

1 Because they are clearly able to supply the
2 market. So in terms of -- so you're saying that these
3 capacity expansions were not necessary or can you just
4 explain that a little bit?

5 MR. FISHER: The press release announcements
6 that I've read in the industry publications indicated --
7 and as indicated here today, are that Eastman's DOTP
8 production capacity exceeds the U.S. market, which would
9 imply that they have material available for export as well,
10 similar to the materials that are exported from other
11 countries and imported to the U.S.

12 MS. MARTINEZ: Thank you. So how would you
13 explain the import trends, in terms of the presence of
14 nonsubject sources and how they decreased over the period?

15 MR. FISHER: As a commodity, certainly
16 petrochemical commodities of scale are important. The
17 impact of the Korea Free Trade Agreement certainly
18 contributes to this, as does the overall domestic demand
19 for the product.

20 So the demand for DOTP is increasing, at the
21 same time, other factors are coming into play that make the
22 Korean imports more competitive.

23 MS. MARTINEZ: You mentioned in your testimony
24 that there is a shift in flooring production from Asia to
25 the U.S. Can you explain that a little bit more why and

1 how is that affecting the market?

2 MR. FISHER: The regulatory pressures mentioned
3 by both parties, as well as some of the press announcements
4 from large retailers as it relates to phthalate content in
5 flooring, as previously mentioned, caused a fundamental
6 shift in the flooring industry to move from DIMP
7 plasticizer and other phthalate-based plasticizers to DOTP
8 during this period of investigation.

9 They are, to my knowledge, the largest single
10 consuming segment of the market of this material.

11 MS. MARTINEZ: But just your mentioning that
12 there's a shift from Asia in flooring production.

13 MR. FISHER: There has been announcements of
14 additional plants being built in the Southeast, and my
15 understanding is that these plants are coming online,
16 taking longer to come online than originally announced or
17 perhaps longer to build than originally announced. Even
18 once they're up and running, they still have to get the
19 billable product coming out at the acceptable rate.

20 So you have a series of announcements, saying
21 this segment of demand will occur at this period of time,
22 but it's taking longer.

23 MS. MARTINEZ: I understand. Thank you for
24 that. I don't think I have anymore questions at this time.

25 MS. BURR: I'd just like to clarify on that

1 point, the quote that Mr. Fisher used is from Eastman's
2 petition, from the annual report they attached to their
3 petition. So we are using Eastman's language.

4 MS. HAINES: Mr. Clark.

5 MR. CLARK: Thank you. Thank you for coming in
6 this morning.

7 You mentioned that DIMP is still a major
8 plasticizer. In what products does DIMP go and why is that
9 not being replaced yet, if there are concerns? Why are we
10 concerned about flooring but not about whatever products
11 the DIMP goes into?

12 MR. FISHER: I'd like to answer that based on my
13 experience and market knowledge, but with the understanding
14 that I'm not an expert in toxicology or these matters.

15 I failed to mention earlier that over the last
16 10 years, I've also spent a tremendous amount of time and
17 effort outside of work advocating on behalf of the U.S.
18 vinyl industry through the plastics association based here
19 in Washington, D.C.

20 I was two term chairman of their flexible vinyl
21 group. I was chairman of the material supplier council,
22 and I'm in my third term on the board of directors. So
23 I've made a number of trips up the Hill to promote, defend
24 and advocate for the entire U.S. vinyl industry.

25 During this time of personal advocacy efforts, I

1 have seen a growing trend in the nonregulatory deselection
2 of different raw materials. What that means is that the
3 shift in public perception, regardless of the media source,
4 is driving sourcing selections from the big box retailers.

5 So they have mandated certain products not
6 contain or though phthalates, as you note accurately
7 earlier.

8 California adding DIMP to Proposition 65
9 certainly accelerated that interest. But these chemicals
10 exist because of their unique properties, and they are not
11 exclusively or wholly interchangeable. Some products
12 simply can't use other plasticizers. And so the producers
13 that I have worked with that were unable to convert easily
14 or cost-effectively have chosen to label their product.

15 The other thing with regards to Prop 65 is that
16 there are exposure levels associated with the label
17 requirements. I'm not an expert in this regard, but some
18 of the producers that use other plasticizers because of
19 their performance properties have decided that the
20 exposures did not require labeling. So you have the
21 ability to label, you have the ability to assess your
22 exposure level, or you have the ability to reformulate into
23 a nonphthalate or nonregulated plasticizer. All of these
24 play into the initial growth in demand for DOTP, I believe,
25 and essentially, the continuing market presence of the

1 other plasticizers.

2 MR. CLARK: Well, thank you. But I'm trying to
3 get at which end products that would be. Are we concerned
4 about flooring because children are on flooring and that's
5 a toxicology issue that a child might be near flooring?
6 And if there's, you know, phthalates in there, that that
7 could be an issue, a child could potentially chew at a
8 corner or something?

9 Why is that our industry of concern and not
10 others, where the DIMP you're saying is still the major
11 general plasticizer?

12 MR. FISHER: DIMP has a larger market share as a
13 general plasticizer I believe than DOTP. Certainly, DIMP
14 and the related orthophthalates, the high molecular weight
15 orthophthalates.

16 DOTPs -- the flooring industry's transition to
17 DOTP, I'm speculating, you know, but I would assign it more
18 to marketability than to performance.

19 And the flooring industry recently was awarded
20 safe use determinations for DIMP by California in
21 accordance with Prop 65, for DIMP content at specific
22 levels in specific materials. So there is the ability to
23 use it, but I think the wholesale transition is more of a
24 marketing related driver.

25 Does that answer your question?

1 MR. CLARK: Yes, thank you.

2 Do you see any other issues that are going to
3 affect the use of DOTP? Again, part of what I was getting
4 at with the first panel was asking, okay, well, is to say
5 is the TSCA going to affect anything? Are there other
6 state regulations? Is there anything other than public
7 perception and marketing that's really driving this?

8 MR. FISHER: My opinion is that public
9 perception and marketing are primary drivers, there are --
10 as noted by the prior panel, the toxicology is widely
11 debated and can be widely debated. It's a rabbit hole
12 probably not best gone down.

13 MR. CLARK: Okay. Thanks. So do you import
14 solely from Korea? Do you import from anybody else? Do
15 you -- do you ever source domestically?

16 MR. FISHER: ALAC's model is import of not only
17 plasticizers but resins and other specialty products used
18 in the vinyl industry from producers in Asia, because of
19 prior experience and existing relationships. And because
20 every single product on our product line exists because
21 U.S. customers asked if we could source it.

22 We do import from other countries. Prior to the
23 implementation of the Korea Free Trade Agreement, a
24 considerable volume of the plasticizer was imported from
25 Taiwan. We also import product from mainland China.

1 But that removal of the 6.5 percent tariff for a
2 commodity product was a significant advantage for the
3 Korean producers.

4 MR. CLARK: Okay. Thank you. Have you changed
5 the way that you're importing from Korea? Have you changed
6 the volumes, the size of the containers, the amount that
7 you're importing at a certain per quarter or per month or
8 whatever?

9 MR. FISHER: The materials are imported via bulk
10 cargo vessels, typically 1000 metric tons. This volume can
11 increase or decrease in a certain range depending on
12 availability of product at the time the ship calls on
13 Korea, and the pricing of the product at the time. But
14 there have been no significant changes in the volumes over
15 the period of investigation, with the exception of most
16 recently a decrease in volumes of DOTP due to availability
17 from our producer.

18 MR. CLARK: Has there -- if you can disclose
19 this here, who are you selling it to? And are you -- are
20 they changing what they're asking for? Are they totally
21 satisfied with the product you're giving them and not
22 asking you to vary it in any way? Does anyone need a
23 particular purity, grade, a niche?

24 MR. FISHER: The cargos are tested and certified
25 for regulatory phthalate compliance by a CPSC-accredited

1 laboratory that verifies the quality and integrity of the
2 material. We have a long established track record of
3 consistently supplying compliant and quality material.

4 The fact that we have our own bulk terminals and
5 take possession of the material in Korea makes us very
6 unique. The other distributors that are not global
7 petrochemical companies with their own production systems,
8 pulling from a tank, don't have their own short terminal
9 inventories at anywhere near the volume that our company
10 does.

11 This creates short lead times and reliability of
12 supply. Using a similar forecast model, we allocate
13 material based on anticipated customer demand, and
14 that's -- that assures the security of supply, which is
15 paramount, along with competitive pricing and quality.

16 MR. CLARK: What I was going to follow up with
17 then, is do you sell out of inventory? You make sure that
18 you're forecasting and you try to make sure that you have
19 enough on hand, so you're selling out of your inventory in
20 the U.S. You're not going back to a supplier and saying,
21 here's the order, can you fill this, and how soon can you
22 get it to me?

23 MR. FISHER: No, because of the transport lead
24 times, you have to manage your inventories locally based on
25 the customer forecasts.

1 MR. CLARK: Thank you. Do any of your -- are
2 your customers fairly loyal, dedicated customers? Are they
3 also -- do some of them source from the U.S. -- from
4 Eastman, and do they switch back and forth depending on
5 availability or price at any given time?

6 MR. FISHER: The majority of our customers
7 multiple source their primary raw materials as a matter of
8 security for their manufacturing operations.

9 Within that ratio, we do maintain a consistent
10 position. We sell based on security of supply, quality and
11 competitiveness, not exclusively price. And that maintains
12 that position, more of a -- more of a true supplier
13 position as opposed to a broker.

14 There are segments of the market that are
15 exclusively price driven. When there's excess material,
16 you can engage those segments. But for the most part, it's
17 not the majority of our business.

18 MR. CLARK: Are there lead time considerations
19 for any of your sales? Is there -- does somebody say,
20 well, I need this, and they haven't anticipated their needs
21 well enough, so they're not able to give you enough lead
22 time such that you're unable to supply them, such that they
23 would then have to turn to Eastman or some other importer
24 or someone that's closer by, because maybe they're far
25 enough away that it would take too long to transport it?

1 MR. FISHER: Trucking is the weak link in bulk
2 chemical distribution. I'm not familiar with Eastman's
3 logistics.

4 We work with a very broad range of carriers and
5 brokers and can typically, perhaps not 100 percent of the
6 time, deliver as needed. We have situations arise where we
7 get calls on extremely short notice, significantly less
8 than the standard one-week lead time, and are able to
9 deliver as needed. And that, in turn, generates customer
10 loyalty and builds the relationship and establishes our
11 position as a reliable supplier.

12 MR. CLARK: Do you have multiple warehouses
13 whenever you're managing your inventories that you're able
14 to respond to things at a regional -- even with the short
15 lead times?

16 MR. FISHER: If you -- our liquid terminals are
17 on the East Coast, so really if you look -- if you plotted
18 our customer base, you would see a relationship to that.
19 There's a practical limit to the transportation costs.

20 MR. CLARK: Okay. Thank you. I guess just
21 again trying to get back to any kind of difference between
22 the product. Do you feel that the product is total --
23 totally a commodity, the DOTP, there is never a difference?
24 Is there ever a time that somebody would contact you trying
25 to make a purchase and then they say, well, I need to

1 buy -- I want to buy something that's U.S.-made or I need
2 something that has been tracked since, I don't know, the
3 raw materials were purchased, so they need to know -- need
4 to have its origin and tracking so that for whatever
5 certification they need, that they would -- either buy
6 America, or because of, I don't know, again I think of the
7 medical industry or the toy industry or whatever, something
8 where it's --

9 MR. FISHER: Sure. Country of origin
10 considerations. And I guess supply chain traceability may
11 impact sourcing decisions for highly regulated components
12 of the marketplace. Historically, we work with more of the
13 general purpose type applications.

14 MR. CLARK: Just trying to get a sense of what
15 all is going on here. Clearly, the bulk of the stuff is
16 going to be more generic. So only a few customers are ever
17 going to need --

18 MR. FISHER: The regulated phthalate compliance
19 is key to some customers, and that's something that we
20 establish on a -- with every shipment.

21 MR. CLARK: Thank you. Those are all the
22 questions I have for now. Thank you.

23 MR. FISHER: Thank you.

24 MS. HAINES: We'll turn to Ms. Dempsey.

25 MS. DEMPSEY: Good afternoon. Thank you for

1 your testimony.

2 I know you said you would address the domestic
3 like product in your posthearing brief. Can you make sure
4 you do that with respect to the six factors the Commission
5 generally considers, and also address whether you agree
6 with Petitioner's definition of the domestic industry?

7 MS. BURR: Yes.

8 MS. DEMPSEY: So from your testimony, I
9 understand that there are several other substitute products
10 for DOTP. Did I understand that correctly? Or you said
11 it's a heavily competitive market and --

12 MR. FISHER: Plasticizer.

13 MS. DEMPSEY: Plasticizers, okay.

14 MR. FISHER: Is a global and very competitive
15 market.

16 MS. DEMPSEY: What other nonphthalate
17 substitutes are there for DOTP?

18 MR. FISHER: DOTP is the only product in our
19 product line. So these comments would be based on my
20 general market knowledge, not a working expertise with
21 them, supplying them to customers.

22 But BASF has a product that they market in this
23 area known as Dinch, D-i-n-c-h, as a nonphthalate
24 alternative.

25 There are also blends of other products, perhaps

1 not a unique plasticizer but compounders can use multiple
2 inputs to achieve the plasticizer requirements in a
3 formulation using different inputs.

4 MS. DEMPSEY: So would those blends incorporate
5 nonphthalate plasticizers or phthalate plasticizers?

6 MR. FISHER: They wouldn't be purchased as a
7 blend. They would purchase the individual components and
8 then incorporate them into their compound. And yes, in
9 this regard, they would be nonphthalate.

10 MS. DEMPSEY: Would you agree with Petitioner
11 that DOTP is the consumer's primary choice in using a
12 nonphthalate plasticizer?

13 MR. FISHER: I would agree with that. I would
14 also agree that its acceptance in the marketplace, based on
15 my experience, on the supply side as increased as the
16 premium between DOTP and other general purpose decreased.

17 MS. DEMPSEY: Thank you. Have purchasers ever
18 come to you to supply DOTP because Eastman would not supply
19 them or could not supply them or cited a shortage?

20 MR. FISHER: I'm not aware of any systemic
21 shortages that have brought sourcing to us. The -- excuse
22 me. The most common reason is multiple supply chain,
23 active multiple supply chains.

24 MS. DEMPSEY: Some of the other reasons would --
25 would you consider pricing of DOTP to be a primary reason

1 for purchasers to come to you?

2 MR. FISHER: Pricing has to be competitive.

3 Typically, in my experience, when somebody is

4 establishing -- I'm sorry.

5 MS. DEMPSEY: Take your time.

6 MR. FISHER: Too much traveling.

7 In my experience, establishing active and

8 maintaining active multiple supply chains, the suppliers

9 involved have to be competitive with one another. That

10 doesn't necessarily mean the -- that doesn't necessarily

11 mean you have to have a lower price every time. They're

12 going to maintain multiple supply chains at comparable

13 pricing.

14 Does that answer your question?

15 MS. DEMPSEY: And you would agree that DOTP is a

16 commodity product.

17 MR. FISHER: I would.

18 MS. DEMPSEY: Other than having a multiple

19 supply source and possibly being price competitive, are

20 there any other reasons that you know that imports are --

21 or subject imports have increased?

22 MR. FISHER: Well, I can speak to my own

23 personal experience.

24 MS. DEMPSEY: Right.

25 MR. FISHER: That's security of supply. Lead

1 time and security of supply. Those are the nonprice
2 factors that our company offers.

3 MS. DEMPSEY: Do you know if DOTP is
4 interchangeable from all sources, such as those from
5 nonsubject countries?

6 MR. FISHER: Based on the customers that I've
7 worked with that qualify material from multiple suppliers,
8 I believe they're interchangeable.

9 MS. DEMPSEY: Last question, you can address in
10 your post-conference brief. But can you address the
11 factors that the Commission considers in determining threat
12 of material injury? Thank you.

13 MS. HAINES: I will turn to Mr. Yost.

14 MR. YOST: Thank you very much for your
15 testimony. I have found it very, very interesting. I have
16 really just one question, and I will ask this of the
17 petitioners as well for them to address in their
18 post-conference brief.

19 Do customers -- I mean, do sales contracts,
20 supply contracts, have raw material escalator or
21 deescalator clauses in them?

22 MR. FISHER: We have been approached by some of
23 the largest consumers to utilize these kinds of pricing
24 models. Their required pricing has been below what we can
25 supply at. So we don't currently supply based on those

1 models.

2 MR. YOST: But those models have -- let's say
3 they use, you know, a floor price or they use an index for
4 the inputs of TPA, DMT, 2 EH, for example, and say, well,
5 if those prices go below, then the price of the DOTP will
6 be adjusted downward or upward as the case may be.

7 MR. FISHER: We have been approached with
8 similar opportunities and have been unable to accept them.

9 MR. YOST: I see. Do customers come in and say,
10 well, we'd like to buy but it has to be sometime in the
11 future, you know, future delivery, and try to build in that
12 kind of an escalator or deescalator clause?

13 MR. FISHER: It doesn't apply to our current
14 model.

15 MR. YOST: Okay. Okay. So my question for
16 Petitioners was, do sales supply contracts have raw
17 material escalator/deescalator clauses, and if so,
18 approximately what percentage of your sales are based on
19 such contracts? Thank you. And that ends my questions.

20 MS. HAINES: Thank you very much. We appreciate
21 your traveling all this way. It was very helpful, thank
22 you.

23 MS. BELL: Petitioners can come forward for
24 closing statements.

25 CLOSING REMARKS OF KEVIN M. O'BRIEN

1 MR. O'BRIEN: Thank you, Ms. Haines and
2 Commission Investigative Staff, for your time and attention
3 today to listen to our presentations.

4 I would like to just briefly respond to some of
5 the testimony you've heard from ALAC and then briefly
6 summarize how we see the case.

7 We believe the issue of whether or not DOTP is a
8 commodity and whether it's interchangeable amongst
9 suppliers is not in dispute. I think -- I think that is
10 the case. I think you've heard testimony from both parties
11 that that is the case, and I believe that the responses you
12 receive in the questionnaires will bear that out.

13 So as a commodity, it is a particularly price
14 sensitive product.

15 The issue was raised of the effect of DINP. But
16 that is one of the phthalate products that consumers are
17 moving away from. So the fact that it's a big presence in
18 the market, while it's interesting, it's not particularly
19 relevant to the Commission's decision in this case.

20 There's no dispute that demand for DOTP is
21 growing. It's growing as a result of consumer preference.

22 There's also no dispute that during the period
23 of investigation, there certainly were times when raw
24 material costs have declined.

25 Now, one would think with increasing demand and

1 declining raw material costs, that profitability should at
2 least be stable or increase. But, in fact, from the
3 financial data, it's quite apparent that that has not
4 occurred. The profitability from being relatively healthy
5 at the beginning of the period of investigation has now
6 been substantially reduced.

7 That is due to unfair pricing. And the unfair
8 pricing aspect, of course, is the Commerce Department's
9 determination to make. But that is the cause of what is
10 eliminating the profitability from the marketplace.

11 The -- again, it's undisputed that Eastman has
12 the capacity to supply the needs of the U.S. market. There
13 hasn't been any shortages during the period of
14 investigation. There's no dispute about that.

15 In terms of establishing the price in the
16 market, the facts simply do not bear that out.

17 As mentioned during our testimony for Eastman,
18 as recently as April 1, Eastman tried to pass on a price
19 increase. It was thoroughly unable to do so, couldn't pass
20 on an increase of any -- of any percentage whatsoever, and
21 in fact, prices continued to decline.

22 So the idea or the proposition that Eastman is a
23 price setter in the market is simply incorrect. Eastman is
24 being buffeted by the low cost imports and has no ability
25 to raise the price, even in the face of increased raw

1 material costs.

2 There was mention of the expansion plans by
3 Eastman, and certainly, capacity has been expanded. But
4 plans for further expansion have been mothballed. There is
5 no business commercial justification for continuing to
6 increase capacity, when the adequate profitability is simply
7 not in the market any longer.

8 So something has to change for -- for Eastman to
9 be able to justify a new capital investment.

10 Much of what was said on behalf of ALAC's
11 witness Eastman would agree with. With respect to the
12 Korean producers and suppliers being very formidable
13 competitors. Like Eastman, they also have certifications
14 for -- by CPSC and other agencies to supply product for
15 various applications. They do have long track records of
16 quality, and they -- they have very impressive facilities,
17 where they can bring in product by the boat load and store
18 it domestically so that there is no lead time advantage
19 that Eastman can take advantage of because the subject
20 merchandise is just as available in U.S. storage tanks for
21 delivery on order by U.S. customers.

22 Again, bearing out that decisions are made on
23 price, not on lead time or delivery.

24 With respect to the multiple sources, we've been
25 over that. And while it is true that some customers may

1 want to have more than one source, the issue of how much
2 gets sold to a particular customer is primarily a basis --
3 made on the basis of price.

4 So that a customer that Eastman would be
5 essentially, essentially selling most of its product to,
6 those customers have moved away from that relationship and
7 have sourced much more Korean product because the pricing
8 is better.

9 So we believe most of these facts are not in
10 dispute. And as we said at the beginning of our
11 presentation this morning, Eastman is looking for a level
12 playing field. The -- we believe the issues of the like
13 product are not in dispute, the issues of domestic industry
14 are not in dispute, the issues of the volume increase and
15 the price deterioration and the effects on Eastman's
16 financials are not in serious dispute.

17 So we believe the Commission should find that
18 there's a reasonable indication of material injury by
19 reason of the subject imports.

20 With respect to threat of imports, we believe
21 that the capacity, which we mentioned several times today
22 and is documented in our petition, is overwhelming in terms
23 of the ability of the Korean producers to direct the
24 subject products toward the U.S. market.

25 So in addition to present material injury, we

1 believe there is an indication of the threat of future
2 industry -- injury as well. And we would ask that the
3 Commission so find.

4 Thank you very much.

5 MS. HAINES: Thank you.

6 CLOSING REMARKS OF MARA M. BURR

7 MS. BURR: On behalf of ALAC, we do appreciate
8 the opportunity to be here today, and just in summary, we
9 want to thank the International Trade Commission and the
10 panel for the questions and the discussion of the industry.

11 From ALAC's perspective, even the amounts and
12 the increase of imports coming in from Korea pale in
13 comparison to the capacity that Eastman has. So to say
14 that a small amount of imports coming in could actually
15 impact the price in the way that's being described is very
16 hard to -- hard to swallow.

17 We also know that there are other factors that
18 impact the price of this product. And it is not just the
19 fact that Korean producers are targeting the U.S. market.
20 We would -- we would disagree with that statement.

21 We believe that the Korean producers are
22 efficient, they are high quality. They did take advantage
23 of a reduction in the tariff, in the Korea U.S. -- or the
24 U.S.-Korea Free Trade Agreement, KorUS. It should be noted
25 that KorUS began negotiations in 2005, concluded in 2007,

1 entered into force in 2012, and obviously producers did
2 know of the zero tariff that was coming online. So
3 certainly they had a chance to look at their products and
4 look at the U.S. market, as well as other markets, because
5 we do know that the Koreans export to other markets, not
6 just the U.S.

7 So as a small company that imports product from
8 Korea, ALAC would see a very difficult business proposition
9 in imposing duties on these imports from Korea and does not
10 see how Eastman has established material injury or the
11 threat of material injury by reason of imports from Korea.

12 So we would hope that you would find in the
13 negative on that question.

14 Thank you.

15 MS. HAINES: Thank you. On behalf of the
16 Commission and the staff, I would like to thank the
17 witnesses who came here today, as well as the counsel, for
18 helping us gain a better understanding of the product and
19 the conditions of competition in the dioctyl terephthalate
20 DOTP industry.

21 Before concluding, let me mention a few dates to
22 keep in mind. The deadline for submission of corrections
23 to the transcript and for submission of post conference
24 briefs is Tuesday, July 26. If briefs contain business
25 proprietary information, a public version is due on

1 Wednesday, July 27.

2 The Commission has tentatively scheduled the
3 vote on these investigations for Friday, August 12, and it
4 will report its determinations to the Secretary of the
5 Department of Commerce on Monday, August 15.

6 Commissioners' opinions will be issued on
7 Monday, August 22.

8 Thank you all for coming. The conference is
9 adjourned.

10 (Whereupon, at 12:21 p.m., the conference was
11 concluded.)

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CERTIFICATE OF REPORTER

TITLE: In The Matter Of: Dioctyl Terephthalate (DOTP)
from Korea
INVESTIGATION NO: 731-TA-1330 (Preliminary)
HEARING DATE: 07-21-16
LOCATION: Washington, D.C.
NATURE OF HEARING: Hearing

I hereby certify that the foregoing/attached transcript is a true, correct and complete record of the above-referenced proceeding(s) of the U.S. International Trade Commission.

DATE: 07-21-2016

SIGNED: Mark A. Jagan
Signature of the Contractor or the
Authorized Contractor's Representative

I hereby certify that I am not the Court Reporter and that I have proofread the above-referenced transcript of the proceedings of the U.S. International Trade Commission, against the aforementioned Court Reporter's notes and recordings, for accuracy in transcription in the spelling, hyphenation, punctuation and speaker identification and did not make any changes of a substantive nature. The foregoing/attached transcript is a true, correct and complete transcription of the proceedings.

SIGNED: Christopher C. Weiskircher
Signature of Proofreader

I hereby certify that I reported the above-referenced proceedings of the U.S. International Trade Commission and caused to be prepared from my tapes and notes of the proceedings a true, correct and complete verbatim recording of the proceedings.

SIGNED: Carmen Smith
Signature of Court Reporter